



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/95098/2010 Rev.8

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 8)

References

The hyperlinks in the document were last accessed online in June 2020.

Foreword

de Abajo F, Rodríguez-Martín S, Lerma L et al. May 2020. [Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study](#). Lancet 2020; May 14; 395.

European Medicines Agency (EMA). Latest data support continued use of ACE inhibitors and ARB medicines during COVID-19 pandemic. [Press Release](#) 9 June 2020

Gnavi, Demaria M, Picariello R et al. [Therapy with agents acting on the renin-angiotensin system and risk of SARS-CoV-2 infection](#). May 2020. Clinical Infectious Diseases, 2020

Jung S, Choi J-C, You SH et al. [Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study](#). Clinical Infectious Diseases, 2020; 22 May. ciaa624, <https://doi.org/10.1093/cid/ciaa624>

Lane JCE, Weaver J, Kostka K et al. [Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study](#). 2020, 31 May. doi: <https://doi.org/10.1101/2020.04.08.20054551>

Mancia G, Rea F, Ludergnani M et al. [Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19](#). New Eng J Med 2020; May 1

Mehta N, [Kalra A](#), Nowacki AS et al. [Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 \(COVID-19\)](#). JAMA Cardiol .Published online May 5, 2020. doi:10.1001/jamacardio.2020.1855.

Morales DR, Conover MM, You SY et al. [Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study](#). <https://doi.org/10.1101/2020.06.11.20125849>

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Pottegård A, Kurz X, Moore N, Christiansen CF, Klungel O. [Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic](#). *Pharmacoepidemiol Drug Saf.* 2020 May 5. doi: 10.1002/pds.5029

Reynolds, HR, Adhikari S, Pulgarin C et al. May 2020. [Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19](#). *New Engl J Med* 2020, May 1. DOI: 10.1056/NEJMoa2008975

Watson J et al. [An open letter to Mehra et al and The Lancet](#). <https://zenodo.org/record/3865253#.XtaoLjIP7ct>

Chapter 1 – Introduction

Ali A, Hartzema A. (2018). Post-Authorization Safety Studies of Medicinal Products. The PASS Book (1st ed.). Academic Press.

Altman, D. (2020). *Practical Statistics for Medical Research*. Chapman & Hall.

Andrews AB, Moore N. (2014). *Mann’s Pharmacovigilance* (3rd ed.). Wiley Blackwell.

Cave, A., Kurz, X., Arlett, P. (2019). Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. *Clinical Pharmacology and Therapeutics*.
<https://doi.org/10.1002/cpt.1426>

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001. (n.d.). Retrieved 14 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF>

Elseviers M, Wettermark B, Almarsdóttir AB, et al. (2016). *Drug Utilization Research: Methods and Applications*. Wiley Blackwell.

Guideline on good pharmacovigilance practices (GVP) Module VIII – Post-authorisation safety studies (Rev 3). European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Hartzema AG, Tilson HH, Chan KA. (2008). *Pharmacoepidemiology and Therapeutic Risk Management* (3rd ed.). Harvey Whitney Books Company.

Hoffmann, W., Latza, U., Baumeister, S. E., Brünger, M., Buttman-Schweiger, N., Hardt, J., Hoffmann, V., Karch, A., Richter, A., Schmidt, C. O., Schmidtman, I., Swart, E., & Berg, N. van den. (2019). Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology. *European Journal of Epidemiology*, 34(3), 301–317. <https://doi.org/10.1007/s10654-019-00500-x>

IEA Good Epidemiology Practices (GPP). (2007). [IEA Publications].
https://ieaweb.org/IEAWeb/Content/IEA_Publications.aspx

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP) (Rev 3). (2015).
<https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Parfrey PS, Barret BJ. (2015). *Clinical epidemiology: practice and methods* (2nd ed.). Human Press.

Porta M, Last JM, Greenland. (2014). *A Dictionary of Epidemiology* (6th ed.). Oxford University Press.

Real-World Evidence. FDA. <https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence>

Rothman K, Greenland S, Lash T. (2020). *Modern Epidemiology* (4th ed.). Lippincott Williams & Wilkins.

Scientific guidance on post-authorisation efficacy studies - EMA. (n.d.). Retrieved 14 May 2020, from https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf

Strom B, Kimmel SE, Hennessy S. (2019). *Pharmacoepidemiology* (6th ed.). Wiley.

Woodward, M. (2014). *Epidemiology: Study Design and Data Analysis* (3rd ed.). Chapman & Hall.

Chapter 2 - Formulating the research question

Brown, P., Brunnhuber, K., Chalkidou, K., Chalmers, I., Clarke, M., Fenton, M., Forbes, C., Glanville, J., Hicks, N. J., Moody, J., Twaddle, S., Timimi, H., & Young, P. (2006). How to formulate research recommendations. *BMJ: British Medical Journal*, 333(7572), 804–806.

<https://doi.org/10.1136/bmj.38987.492014.94>

European Medicines Agency. (n.d.). European Medicines Agency. Retrieved 14 May 2020, from <https://www.ema.europa.eu/en>

Guideline on good pharmacovigilance practices (GVP). European Medicines Agency. Retrieved 27 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP) (Rev 3). (2015). International Society for Pharmacoepidemiology. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Position paper on how to best formulate research recommendations - EUnetHTA. (n.d.). Retrieved 14 May 2020, from https://www.eunetha.eu/wp-content/uploads/2018/01/eunetha_position_paper_on_research_recommendations_0-1.pdf

The criteria to select and prioritise health technologies for additional evidence generation - EUnetHTA. (n.d.). Retrieved 14 May 2020, from <https://eunetha.eu/wp-content/uploads/2018/01/Selection-prioritisation-criteria-1.pdf>

Willame, C., Baril, L., van den Bosch, J., Ferreira, G. L. C., Williams, R., Rosillon, D., & Cohet, C. (2016). Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies. *Pharmacoepidemiology and Drug Safety*, 25(12), 1397–1406. <https://doi.org/10.1002/pds.4081>

Chapter 3 - Development of the study protocol

Agency for Healthcare Research and Quality (AHRQ). (n.d.). Retrieved 14 May 2020, from <https://www.ahrq.gov/>

Commission Implementing Regulation (EU) No 520/2012. (n.d.). Retrieved 14 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide - Effective Health Care Program - AHRQ. (2013). Agency for Healthcare Research and Quality. <https://effectivehealthcare.ahrq.gov/products/observational-cer-protocol/research>

Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001. (n.d.). Retrieved 14 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF>

ENCePP Checklist for Study Protocols. (n.d.). ENCePP. Retrieved 14 May 2020, from http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml

EU PAS Register. (n.d.). Retrieved 27 May 2020, from <http://www.encepp.eu/encepp/studiesDatabase.jsp>

Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies - EMA. (n.d.). Retrieved 14 May 2020, from https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies - EMA. (n.d.). Retrieved 14 May 2020, from https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf

Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) European Medicines Agency. Retrieved 26 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Guideline on good pharmacovigilance practices (GVP) Module VIII – Post-authorisation safety studies (Rev 3) European Medicines Agency. Retrieved 15 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP) (Rev 3). (2015). International Society for Pharmacoepidemiology. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Research, C. for D. E. and R., Center for Biologics Evaluation and Research. (n.d.). FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets - FDA. Retrieved 14 May 2020, from <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

The European Union electronic Register of Post-Authorisation Studies (EU PAS Register). (n.d.). ENCePP. Retrieved 14 May 2020, from <http://www.encepp.eu/encepp/studiesDatabase.jsp>

Volume 10 of the Rules Governing Medicinal Products in the European Union. Public Health - European Commission. Retrieved 14 May 2020, from https://ec.europa.eu/health/documents/eudralex/vol-10_en

Chapter 4 - Approaches to data collection

Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). European Medicines Agency. Retrieved 26 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

4.1 – Primary data collection

Abenham, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B. (1996). Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. *New England Journal of Medicine*, 335(9), 609–616.
<https://doi.org/10.1056/NEJM199608293350901>

Clinical trials - Regulation EU No 536/2014. (n.d.). Public Health - European Commission. Retrieved 18 May 2020, from https://ec.europa.eu/health/human-use/clinical-trials/regulation_en

Artime, E., Qizilbash, N., Garrido-Esteba, M, Vora, P, Soriano-Gabarró, M, Asimwe, A, Pocock, S. (2019). Are Risk Minimization Measures for Approved Drugs in Europe Effective? A Systematic Review. Expert Opinion on Drug Safety. <https://doi.org/10.1080/14740338.2019.1612875>

EudraLex - Volume 10 - Clinical trials guidelines. (n.d.). Public Health - European Commission. Retrieved 18 May 2020, from https://ec.europa.eu/health/documents/eudralex/vol-10_en

Fayers PM, Machin D. (2007). *Quality of Life: the assessment, analysis and interpretation of patient-related outcomes* (2nd ed.). Wiley.

FDA - Guidance on Survey Methodologies to Assess REMS Goals That Relate to Knowledge. (2019). Center for Drug Evaluation and Research Center for Biologics Evaluation and Research.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/survey-methodologies-assess-rems-goals-relate-knowledge>

FDA - REMS Assessment: Planning and Reporting. (n.d.). Retrieved 4 June 2020, from <https://www.fda.gov/media/119790/download>

Guideline on good pharmacovigilance practices (GVP) Module VIII – Post-authorisation safety studies (Rev 3). European Medicines Agency. Retrieved 18 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2). European Medicines Agency. Retrieved 4 June 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Groves RM, Fowler FJ, Couper MP et al. (2009). *Survey Methodology* (2nd ed.). Wiley.

ICH E6 (R2) Good clinical practice European Medicines Agency. Retrieved 18 May 2020, from <https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice>

Kaufman, D. W., Rosenberg, L., & Mitchell, A. A. (2001). Signal generation and clarification: use of case-control data. *Pharmacoepidemiology and Drug Safety*, 10(3), 197–203.
<https://doi.org/10.1002/pds.571>

Kish L. (1995). *Survey Sampling*. Wiley.

My, S., A, R., P, B., Pgm, M., S, F., E, F., & Eh, M. (2018). The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products. *Drug Safety*. <https://doi.org/10.1007/s40264-017-0619-x>

Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., Mockenhaupt, M., Paoletti, C., Shapiro, S., Shear, N., Schöpf, E., & Kaufman, D. W. (1995). Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis. *New England Journal of Medicine*, 333(24), 1600–1608.
<https://doi.org/10.1056/NEJM199512143332404>

Shapiro, S. (1983). The design of a study of the drug etiology of agranulocytosis and aplastic anemia. *European Journal of Clinical Pharmacology*, 24(6), 833–836. <https://doi.org/10.1007/BF00607096>

Standard Definitions Final Dispositions of Case Codes and Outcome Rates for Surveys - AAPOR. (n.d.). Retrieved 4 June 2020, from https://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf

4.2 - Secondary use of data

Cave, A, Kurz, X, Arlett, P. (2019). Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. *Clinical Pharmacology and Therapeutics*. <https://doi.org/10.1002/cpt.1426>

Berger, M. L., Sox, H., Willke, R. J., Brixner, D. L., Eichler, H.-G., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., Wang, S. V., Watkins, J., & Mullins, C. D. (2017). Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. *Value in Health*, 20(8), 1003-1008. <https://doi.org/10.1016/j.jval.2017.08.3019>

ENCePP Resources Database. (n.d.). ENCePP. Retrieved 10 June 2020, from <http://www.encepp.eu/encepp/resourcesDatabase.jsp>

FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

FDA Real-World Evidence. FDA. <https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence>

Hall, Gc., Sauer, B., Bourke, A., Brown, Js., Reynolds, Mw., LoCasale, L. (2012). Guidelines for Good Database Selection and Use in Pharmacoepidemiology Research. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.2229>

Hoffmann, W., Latza, U., Baumeister, S. E., Brünger, M., Buttmann-Schweiger, N., Hardt, J., Hoffmann, V., Karch, A., Richter, A., Schmidt, C. O., Schmidtman, I., Swart, E., & Berg, N. van den. (2019). Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology. *European Journal of Epidemiology*, 34(3), 301–317. <https://doi.org/10.1007/s10654-019-00500-x>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (2015). International Society for Pharmacoepidemiology. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Schneeweiss, S., Avorn, J. (2005). A Review of Uses of Health Care Utilization Databases for Epidemiologic Research on Therapeutics. *Journal of Clinical Epidemiology*. <https://doi.org/10.1016/j.jclinepi.2004.10.012>

Strom B, Kimmel SE, Hennessy S. (2019). *Pharmacoepidemiology* (6th ed.). Wiley.

4.3 - Patient registries

CHMP Guideline on Conduct of Pharmacovigilance for Medicines Used by the Paediatric Population - EMA. (n.d.). Retrieved 15 May 2020, from https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf

- Emilsson, L., Lindahl, B., Köster, M., Lambe, M., & Ludvigsson, J. F. (2015). Review of 103 Swedish Healthcare Quality Registries. *Journal of Internal Medicine*, 277(1), 94–136. <https://doi.org/10.1111/joim.12303>
- ENCePP Resources Database. (n.d.). ENCePP. Retrieved 15 May 2020, from <http://www.encepp.eu/encepp/resourcesDatabase.jsp>
- EUnetHTA Joint Action 3 (2016 - 2020). (n.d.). EUnetHTA. Retrieved 15 May 2020, from <https://eunetha.eu/ja3-archive/>
- EUROCAT. (n.d.). Retrieved 15 May 2020, from <http://www.eurocat-network.eu/>
- FDA Guidance for Industry Establishing Pregnancy Exposure Registries. (n.d.). Retrieved 15 May 2020, from <https://www.fda.gov/media/75607/download>
- Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M. (2015). Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. *BMJ : British Medical Journal*, 350, h1798. <http://www.bmj.com/content/bmj/350/bmj.h1798.full.pdf>
- Guideline on good pharmacovigilance practices (GVP) Module VIII – Post-authorisation safety studies (Rev 3). (2018, September 17). European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>
- JRC EU RD Platform releases the Set of Common Data Elements for RD Registration. (n.d.). ERA-Net E-Rare. Retrieved 15 May 2020, from <http://www.erare.eu/news/jrc-eu-rd-platform-releases-set-common-data-elements-rd-registration>
- Lauer, M. S., & D'Agostino, R. B. (2013). The randomized registry trial--the next disruptive technology in clinical research? *The New England Journal of Medicine*, 369(17), 1579–1581. <https://doi.org/10.1056/NEJMp1310102>
- Li, G., Sajobi, T. T., Menon, B. K., Korngut, L., Lowerison, M., James, M., Wilton, S. B., Williamson, T., Gill, S., Drogos, L. L., Smith, E. E., Vohra, S., Hill, M. D., Thabane, L., & 2016 Symposium on Registry-Based Randomized Controlled Trials in Calgary. (2016). Registry-based randomized controlled trials--what are the advantages, challenges, and areas for future research? *Journal of Clinical Epidemiology*, 80, 16–24. <https://doi.org/10.1016/j.jclinepi.2016.08.003>
- McGettigan, P., Alonso Olmo, C., Plueschke, K., Castillon, M., Noguera Zondag, D., Bahri, P., Kurz, X., & Mol, P. G. M. (2019). Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments. *Drug Safety*, 42(11), 1343–1351. <https://doi.org/10.1007/s40264-019-00848-9>
- Norwegian Patient Registry. (n.d.). Retrieved 15 May 2020, from <https://helsedirektoratet.no/english/norwegian-patient-registry>
- Pacurariu, A., Plueschke, K., Olmo, C. A., & Kurz, X. (2018). Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. *Pharmacoepidemiology and Drug Safety*, 27(7), 823–826. <https://doi.org/10.1002/pds.4449>
- PARENT - Methodological guidelines and recommendations for efficient and rational governance of patient registries. (n.d.). Retrieved 11 June 2020, from https://ec.europa.eu/health/sites/health/files/ehealth/docs/patient_registries_guidelines_en.pdf

Patient registries. (n.d.). European Medicines Agency. Retrieved 15 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/patient-registries>

PharmaChild PRINTO. (n.d.). Paediatric Rheumatology INternational Trials Organization. Retrieved 15 May 2020, from <https://www.printo.it/projects/ongoing/15>

Qualification Opinion - The European Cystic Fibrosis Society Patient Registry (ECFSPR) - EMA. (n.d.). Retrieved 15 May 2020, from https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr_en.pdf

Qualification opinion on Cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry - EMA. (n.d.). Retrieved 15 May 2020, from https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-cellular-therapy-module-european-society-blood-marrow-transplantation-ebmt_en.pdf

Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition Addendum (Overview). (2018). Agency for Healthcare Research and Quality. <https://effectivehealthcare.ahrq.gov/products/registries-guide-3rd-edition-addendum/overview>

Registry Evaluation and Quality Standards Tool and its vision paper (REQueST). (n.d.). EUnetHTA. Retrieved 15 May 2020, from <https://eunetha.eu/request-tool-and-its-vision-paper/>

Research, C. for D. E. and. (2020). Draft Postapproval Pregnancy Safety Studies Guidance for Industry - FDA. FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies-guidance-industry>

Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015). The Danish National Patient Registry: a review of content, data quality, and research potential. *Clinical Epidemiology*, 7, 449–490. <https://doi.org/10.2147/CLEP.S91125>

Scientific guidance on post-authorisation efficacy studies - EMA. (n.d.). Retrieved 11 June 2020, from https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf

Swedish National Patient Register. (n.d.). SITENAME. Retrieved 15 May 2020, from <https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-national-patient-register/>

Systematic overview of data sources for drug safety in pregnancy research. (n.d.). Retrieved 15 May 2020, from http://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf

UK Renal Registry. (n.d.). UK Renal Registry. Retrieved 19 June 2020, from <https://www.renalreg.org/>

4.4 - Spontaneous reports

Alvarez, Y, Hidalgo, A., Maignen, F., Slattery, J (2010, June 1). Validation of Statistical Signal Detection Procedures in Eudravigilance Post-Authorization Data: A Retrospective Evaluation of the Potential for Earlier Signalling. *Drug Safety*. <https://doi.org/10.2165/11534410-000000000-00000>

EudraVigilance. European Medicines Agency. Retrieved 18 May 2020, from <https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance>

Kreimeyer, K., Menschik, D., Winiacki, S., Paul, W., Barash, F., Woo, E. J., Alimchandani, M., Arya, D., Zinderman, C., Forshee, R., & Botsis, T. (2017). Using Probabilistic Record Linkage of Structured and

Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems. *Drug Safety*, 40(7), 571–582. <https://doi.org/10.1007/s40264-017-0523-4>

Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. (n.d.). COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. Retrieved 20 May 2020, from <https://cioms.ch/publications/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/>

Tregunno, Pm., Fink, Db., Fernandez-Fernandez, C., Lázaro-Bengoa, E, Norén, Gn. (2014). Performance of Probabilistic Method to Detect Duplicate Individual Case Safety Reports. *Drug Safety*. <https://doi.org/10.1007/s40264-014-0146-y>

WHO-UMC - The Global Individual Case Safety Reports Database System (VigiBase). (n.d.). Retrieved 18 May 2020, from <https://www.who-umc.org/vigibase/vigibase/>

Wisniewski AFZ, Juhlin K, Vestergaard Laursen M, Macia MM, Manlik K, Pinkston VK, Seabroke S, Slattery J (PROTECT project). (n.d.). Characterization of databases (DB) used for signal detection (SD). <http://www.imi-protect.eu/documents/WisniewskietalCharacterisationofdatabasesusedorsignaldetectionposterfinalICPE2012.pdf>

4.5 - Social media

Audeh, B., Bellet, F., Beyens, M.-N., Louët, A. L.-L., & Bousquet, C. (2020). Use of Social Media for Pharmacovigilance Activities: Key Findings and Recommendations from the Vigi4Med Project. *Drug Safety*, 1–17. <https://doi.org/10.1007/s40264-020-00951-2>

Banerjee, Ak. et al. (2012). Web-based Patient-Reported Outcomes in Drug Safety and Risk Management: Challenges and Opportunities? *Drug Safety*. <https://doi.org/10.2165/11632390-000000000-00000>

Bhattacharya, M., Snyder, S., Malin, M., Truffa, M. M., Marinic, S., Engelmann, R., & Raheja, R. R. (2017). Using Social Media Data in Routine Pharmacovigilance: A Pilot Study to Identify Safety Signals and Patient Perspectives. *Pharmaceutical Medicine*, 31(3), 167–174. <https://doi.org/10.1007/s40290-017-0186-6>

Brosch, S. et al. (2019). Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe. *Drug Safety*. <https://doi.org/10.1007/s40264-019-00811-8>

Caster, O., Dietrich, J., Kürzinger, M.-L., Lerch, M., Maskell, S., Norén, G. N., Tcherny-Lessenot, S., Vroman, B., Wisniewski, A., & Stekelenborg, J. van. (2018). Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. *Drug Safety*, 41(12), 1355–1369. <https://doi.org/10.1007/s40264-018-0699-2>

Cocos, A. et al. (2017). Deep Learning for Pharmacovigilance: Recurrent Neural Network Architectures for Labeling Adverse Drug Reactions in Twitter Posts. *Journal of the American Medical Informatics Association : JAMIA*. <https://doi.org/10.1093/jamia/ocw180>

Coloma, P. M., Becker, B., Sturkenboom, M. C. J. M., van Mulligen, E. M., & Kors, J. A. (2015). Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies. *Drug Safety*, 38(10), 921–930. <https://doi.org/10.1007/s40264-015-0333-5>

EDPS Opinion 1/2015 Mobile Health-Reconciling technological innovation with data protection. (n.d.). Retrieved 5 June 2020, from https://edps.europa.eu/sites/edp/files/publication/15-05-21_mhealth_en_0.pdf

ENISA - European Union Agency for Cybersecurity. (n.d.). [Plone Site]. Retrieved 5 June 2020, from <https://www.enisa.europa.eu>

ENISA - Smartphone Secure Development Guidelines. (n.d.). [Report/Study]. ENISA - European Union Agency for Cybersecurity. Retrieved 5 June 2020, from <https://www.enisa.europa.eu/publications/smartphone-secure-development-guidelines-2016>

European Commission's Digital Single Market Glossary. (n.d.). Shaping Europe's Digital Future - European Commission. Retrieved 5 June 2020, from <https://ec.europa.eu/digital-single-market/en/glossary>

Gattepaille, L. M., Vidlin, S. H., Bergvall, T., Pierce, C. E., & Ellenius, J. (2020). Prospective Evaluation of Adverse Event Recognition Systems in Twitter: Results from the Web-RADR Project. *Drug Safety*, 1–12. <https://doi.org/10.1007/s40264-020-00942-3>

Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Powell, Ge. et al. (2016). Social Media Listening for Routine Post-Marketing Safety Surveillance. *Drug Safety*. <https://doi.org/10.1007/s40264-015-0385-6>

General Data Protection Regulation (GDPR) Compliance Guidelines. (n.d.). GDPR.Eu. Retrieved 5 June 2020, from <https://gdpr.eu/>

Sloane, R. et al. (2015). Social Media and Pharmacovigilance: A Review of the Opportunities and Challenges. *British Journal of Clinical Pharmacology*. <https://doi.org/10.1111/bcp.12717>

Stekelenborg, J. van, Ellenius, J., Maskell, S., Bergvall, T., Caster, O., Dasgupta, N., Dietrich, J., Gama, S., Lewis, D., Newbould, V., Brosch, S., Pierce, C. E., Powell, G., Ptaszyńska-Neophytou, A., Wiśniewski, A. F. Z., Tregunno, P., Norén, G. N., & Pirmohamed, M. (2019). Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. *Drug Safety*, 42(12), 1393–1407. <https://doi.org/10.1007/s40264-019-00858-7>

4.6 - Research networks for multi-database studies

ADVANCE - VAccine monitoring Collaboration for Europe. (n.d.). VAC4EU. Retrieved 20 May 2020, from <https://vac4eu.org/>

Arrhythmogenic potential of drugs | ARITMO Project | FP7 |CORDIS | European Commission. (n.d.). Retrieved 16 June 2020, from <https://cordis.europa.eu/project/id/241679>

Becker, Bfh et al. (2017). CodeMapper: Semiautomatic Coding of Case Definitions. A Contribution From the ADVANCE Project. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.4245>

CNODES - Canadian Network for Observational Drug Effects Studies. (n.d.). Retrieved 20 May 2020, from <https://www.cnodes.ca/>

EHDEN - European Health Data Evidence Network. (n.d.). Ehdn.Eu. Retrieved 20 May 2020, from <https://www.ehden.eu/>

EMIF. (n.d.). Retrieved 20 May 2020, from <http://www.emif.eu/>

ENCePP Resources Database. (n.d.). ENCePP. Retrieved 20 May 2020, from <http://www.encepp.eu/encepp/resourcesDatabase.jsp>

EU-ADR Project | FP7 | CORDIS | European Commission. (n.d.). Retrieved 16 June 2020, from <https://cordis.europa.eu/project/id/215847>

EUROmediCAT. (n.d.). Retrieved 20 May 2020, from <http://www.euromedicat.eu/>

Candore, G., Hedenmalm, K., Slattery, J., Cave, A., Kurz, X., Arlett, P. (2020). Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?: A Validation Study Based on Prescribing Codeine in Children. *Clinical Pharmacology and Therapeutics*. <https://doi.org/10.1002/cpt.1785>

Trifirò, G., Coloma, Pm., Rijnbeek, Pr., Romio, S., Mosseveld, B., Weibel, D., Bonhoeffer, J., Schuemie, M., van der Lis, J, Sturkenboom, M. (2014). Combining Multiple Healthcare Databases for Postmarketing Drug and Vaccine Safety Surveillance: Why and How? *Journal of Internal Medicine*. <https://doi.org/10.1111/joim.12159>

Gini, R., Schuemie, M., Brown, J., Ryan, P., Vacchi, E., Coppola, M., Cazzola, W., Coloma, P., Berni, R., Diallo, G., Oliveira, J. L., Avillach, P., Trifirò, G., Rijnbeek, P., Bellentani, M., Lei, J. van D., Klazinga, N., & Sturkenboom, M. (2016). Data Extraction And Management In Networks Of Observational Health Care Databases For Scientific Research: A Comparison Among EU-ADR, OMOP, Mini-Sentinel And MATRICE Strategies. *EGEMs (Generating Evidence & Methods to Improve Patient Outcomes)*, 4(1). <https://doi.org/10.13063/2327-9214.1189>

GRIP - Global Research in Paediatrics - CORDIS | European Commission. (n.d.). Retrieved 16 June 2020, from <https://cordis.europa.eu/project/id/261060>

Improving Consistency and Understanding of Discrepancies of Findings from Pharmacoepidemiological Studies: the IMI PROTECT Project: Pharmacoepidemiology and Drug Safety: Vol 25, No S1. (n.d.). Wiley Online Library. Retrieved 20 May 2020, from <https://onlinelibrary.wiley.com/toc/10991557/25/S1>

Innovative Medicines Initiative (IMI). (n.d.). IMI Innovative Medicines Initiative. Retrieved 20 May 2020, from <http://www.imi.europa.eu/>

Sketris, Is et al. (2020). Building a Framework for the Evaluation of Knowledge Translation for the Canadian Network for Observational Drug Effect Studies. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.4738>

Sultana, J et al. (2019). All-cause Mortality and Antipsychotic Use Among Elderly Persons With High Baseline Cardiovascular and Cerebrovascular Risk: A Multi-Center Retrospective Cohort Study in Italy. *Expert Opinion on Drug Metabolism & Toxicology*. <https://doi.org/10.1080/17425255.2019.1561860>

Kieler, H., Artama, M., Engeland, A., Ericsson, Ö., Furu, K., Gissler, M., Nielsen, R. B., Nørgaard, M., Stephansson, O., Valdimarsdottir, U., Zoega, H., & Haglund, B. (2012). Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. *BMJ*, 344, d8012. <https://doi.org/10.1136/bmj.d8012>

Klungel Olaf H., Kurz Xavier, Groot Mark C. H., Schlienger Raymond G., Tcherny-Lessenot Stephanie, Grimaldi Lamiae, Ibáñez Luisa, Groenwold Rolf H. H., & Reynolds Robert F. (2016). Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. *Pharmacoepidemiology and Drug Safety*, 25(S1), 156–165. <https://doi.org/10.1002/pds.3968>

Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., Alser, O., Alshammari, T. M., Biedermann, P., Burn, E., Casajust, P., Conover, M., Culhane, A. C., Davydov, A., DuVall, S. L., Dymshyts, D., Bertolín, S. F., Fišter, K., Hardin, J., ... Prieto-Alhambra, D. (2020). Safety

of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. MedRxiv, 2020.04.08.20054551. <https://doi.org/10.1101/2020.04.08.20054551>

OHDSI – Observational Health Data Sciences and Informatics. (n.d.). Retrieved 20 May 2020, from <https://www.ohdsi.org/>

OMOP Common Data Model – OHDSI. (n.d.). Retrieved 20 May 2020, from <https://www.ohdsi.org/data-standardization/the-common-data-model/>

Overhage, J. M., Ryan, P. B., Reich, C. G., Hartzema, A. G., & Stang, P. E. (2012). Validation of a common data model for active safety surveillance research. *Journal of the American Medical Informatics Association : JAMIA*, 19(1), 54–60. <https://doi.org/10.1136/amiainl-2011-000376>

PROTECT. (n.d.). Retrieved 20 May 2020, from <http://www.imi-protect.eu/about.shtml>

Flyn, R et al. (2020). Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. *Clinical Pharmacology and Therapeutics*. <https://doi.org/10.1002/cpt.1775>

Gini, R. et al. (2020). Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model. *Clinical Pharmacology and Therapeutics*. <https://doi.org/10.1002/cpt.1833>

Izem, R. et al. (2020). Quantifying How Small Variations in Design Elements Affect Risk in an Incident Cohort Study in Claims. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.4892>

Research, C. for D. E. and. (n.d.). FDA’s Sentinel Initiative. FDA. Retrieved 20 May 2020, from <https://www.fda.gov/safety/fdas-sentinel-initiative>

Roberto, G., Leal, I., Sattar, N., Loomis, A. K., Avillach, P., Egger, P., Wijngaarden, R. van, Ansell, D., Reisberg, S., Tammesoo, M.-L., Alavere, H., Pasqua, A., Pedersen, L., Cunningham, J., Tramontan, L., Mayer, M. A., Herings, R., Coloma, P., Lapi, F., ... Gini, R. (2016). Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. *PLOS ONE*, 11(8), e0160648. <https://doi.org/10.1371/journal.pone.0160648>

Safety Evaluation of Adverse Reactions in Diabetes | SAFEGUARD Project | FP7 |CORDIS | European Commission. (n.d.). Retrieved 16 June 2020, from <https://cordis.europa.eu/project/id/282521>

Slattery, J., Kurz, X. (2020). Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness? *Pharmacoepidemiology and Drug Safety*, n/a(n/a). <https://doi.org/10.1002/pds.5005>

SOS NSAIDS PROJECT. (n.d.). Retrieved 26 May 2020, from <https://www.sos-nsaids-project.org/>

The U.S. Food and Drug Administration’s Mini-Sentinel Program: *Pharmacoepidemiology and Drug Safety*: Vol 21, No S1. (n.d.). Wiley Online Library. Retrieved 20 May 2020, from <https://onlinelibrary.wiley.com/toc/10991557/21/S1>

Vaccine Safety Datalink (VSD). (n.d.). Retrieved 20 May 2020, from <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>

Xu, Y., Zhou, X., Suehs, B. T., Hartzema, A. G., Kahn, M. G., Moride, Y., Sauer, B. C., Liu, Q., Moll, K., Pasquale, M. K., Nair, V. P., & Bate, A. (2015). A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. *Drug Safety*, 38(8), 749–765. <https://doi.org/10.1007/s40264-015-0297-5>

Chapter 5 - Study design and methods

5.1 - Definition and validation of drug exposure, outcomes and covariates

A review of uses of health care utilization databases for epidemiologic research on therapeutics. (2005). *Journal of Clinical Epidemiology*, 58(4), 323–337.

<https://doi.org/10.1016/j.jclinepi.2004.10.012>

B. Strom, S.E. Kimmel, S. Hennessy. (2012). *Pharmacoepidemiology* (5th ed.). Wiley.

Brenner, H., & Gefeller, O. (1993). Use of the Positive Predictive Value to Correct for Disease Misclassification in Epidemiologic Studies. *American Journal of Epidemiology*, 138(11), 1007–1015.

<https://doi.org/10.1093/oxfordjournals.aje.a116805>

Brighton Collaboration case definitions. (n.d.). Retrieved 19 June 2020, from

<https://www.brightoncollaboration.org/case-definitions>

Brunelli, S. M., Gagne, J. J., Huybrechts, K. F., Wang, S. V., Patrick, A. R., Rothman, K. J., & Seeger, J. D. (2013). Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. *Pharmacoepidemiology and Drug Safety*, 22(5), 542–550.

<https://doi.org/10.1002/pds.3434>

Carnahan, R. M., & Moores, K. G. (2012). Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.

Pharmacoepidemiology and Drug Safety, 21(S1), 82–89. <https://doi.org/10.1002/pds.2321>

ClinicalCodes Repository. (n.d.). Retrieved 19 June 2020, from

<https://clinicalcodes.rss.mhs.man.ac.uk/>

Davé, S., Petersen, I. (2009). Creating Medical and Drug Code Lists to Identify Cases in Primary Care Databases. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.1770>

Greenland, S. (1996). Basic Methods for Sensitivity Analysis of Biases. *International Journal of Epidemiology*, 25(6), 1107–1116. <https://doi.org/10.1093/ije/25.6.1107-a>

Lash T, Fox MP, Fink AK. (2009). *Applying quantitative bias analysis to epidemiologic data*. Springer-Verlag.

Lee, Wj., Lee, Ta., Pickard, As, Shoaibi, A, Schumock, Gt. (2015, August). Using Linked Electronic Data to Validate Algorithms for Health Outcomes in Administrative Databases. *Journal of Comparative Effectiveness Research*. <https://doi.org/10.2217/cer.15.14>

M. Elseviers, B. Wettermark, A.B. Almarsdottir. (2016). *Drug Utilization Research. Methods and Applications*. Wiley Blackwell.

Khan, Nf., Harrison, Se., Rose, Pw. (2010). Validity of Diagnostic Coding Within the General Practice Research Database: A Systematic Review. *The British Journal of General Practice: The Journal of the Royal College of General Practitioners*. <https://doi.org/10.3399/bjgp10X483562>

Pottegard, A., Christensen, Rd, Houji, A., Christiansen, Cb, Paulsen, Ma, Thomsen, JI, Hallas, J. (2014). Primary Non-Adherence in General Practice: A Danish Register Study. *European Journal of Clinical Pharmacology*. <https://doi.org/10.1007/s00228-014-1677-y>

Quantitative Bias Analysis Methodology Development: Sequential Bias Adjustment for Outcome Misclassification. (n.d.). Retrieved 19 June 2020, from

https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel_Methods_Sequential_bias.pdf

5.2 - Bias (systematic error)

Fewell, Z., Davey Smith, G., & Sterne, J. A. C. (2007). The Impact of Residual and Unmeasured Confounding in Epidemiologic Studies: A Simulation Study. *American Journal of Epidemiology*, 166(6), 646–655. <https://doi.org/10.1093/aje/kwm165>

Grobbée, D. E., & Hoes, A. W. (1997). Confounding and indication for treatment in evaluation of drug treatment for hypertension. *BMJ*, 315(7116), 1151–1154. <https://doi.org/10.1136/bmj.315.7116.1151>

Horwitz, R. I., & Feinstein, A. R. (1978). Alternative Analytic Methods for Case-Control Studies of Estrogens and Endometrial Cancer. *New England Journal of Medicine*, 299(20), 1089–1094. <https://doi.org/10.1056/NEJM197811162992001>

Joffe, M. M. (2000). Confounding by indication: the case of calcium channel blockers. *Pharmacoepidemiology and Drug Safety*, 9(1), 37–41. [https://doi.org/10.1002/\(SICI\)1099-1557\(200001/02\)9:1<37::AID-PDS471>3.0.CO;2-U](https://doi.org/10.1002/(SICI)1099-1557(200001/02)9:1<37::AID-PDS471>3.0.CO;2-U)

Rothman, K., Greenland, S., Lash, T. (2008). *Modern Epidemiology*. Lippincott Williams & Wilkins.

Kiri, V. A., & MacKenzie, G. (2009). RE: "IMMORTAL TIME BIAS IN PHARMACOEPIDEMIOLOGY". *American Journal of Epidemiology*, 170(5), 667–668. <https://doi.org/10.1093/aje/kwp239>

Klungel, O. et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. (2004). *Journal of Clinical Epidemiology*, 57(12), 1223–1231. <https://doi.org/10.1016/j.jclinepi.2004.03.011>

Lévesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010). Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *BMJ*, 340. <https://doi.org/10.1136/bmj.b5087>

Ma, L. (1999). The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, Results, New Analyses and the Healthy User Effect. *Human Reproduction Update*. <https://doi.org/10.1093/humupd/5.6.707>

McMahon, A. D. (2003). Approaches to combat with confounding by indication in observational studies of intended drug effects. *Pharmacoepidemiology and Drug Safety*, 12(7), 551–558. <https://doi.org/10.1002/pds.883>

Moodie, E. E. M., & Stephens, D. A. (2010). Using Directed Acyclic Graphs to detect limitations of traditional regression in longitudinal studies. *International Journal of Public Health*, 55(6), 701–703. <https://doi.org/10.1007/s00038-010-0184-x>

Salas, M., Hotman, A., & Stricker, B. H. (1999). Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. *American Journal of Epidemiology*, 149(11), 981–983. <https://doi.org/10.1093/oxfordjournals.aje.a009758>

Schneeweiss, S. (2006). Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. *Pharmacoepidemiology and Drug Safety*, 15(5), 291–303. <https://doi.org/10.1002/pds.1200>

Sensitivity Analysis. (n.d.). Retrieved 23 June 2020, from <https://www.drugepi.org/dope/software#Sensitivity>

Strom, B.L., Kimmell, S.E., & Hennessy, S. (2012). *Pharmacoepidemiology* (5th ed.). Wiley.

Suissa, S. (2007). Immortal time bias in observational studies of drug effects. *Pharmacoepidemiology and Drug Safety*, 16(3), 241–249. <https://doi.org/10.1002/pds.1357>

Suissa, S. (2008). Immortal Time Bias in Pharmacoepidemiology. *American Journal of Epidemiology*, 167(4), 492–499. <https://doi.org/10.1093/aje/kwm324>

Suissa, S. (2008). Immeasurable Time Bias in Observational Studies of Drug Effects on Mortality. *American Journal of Epidemiology*, 168(3), 329–335. <https://doi.org/10.1093/aje/kwn135>

Suissa, S., & Azoulay, L. (2012). Metformin and the Risk of Cancer: Time-related biases in observational studies. *Diabetes Care*, 35(12), 2665–2673. <https://doi.org/10.2337/dc12-0788>

Surveillance Bias in Outcomes Reporting | Venous Thromboembolism | JAMA | JAMA Network. (n.d.). Retrieved 23 June 2020, from <https://jamanetwork.com/journals/jama/fullarticle/900883>

Gerhard, T. (2008). Bias: Considerations for Research Practice. *American Journal of Health-System Pharmacy*: AJHP: Official Journal of the American Society of Health-System Pharmacists. <https://doi.org/10.2146/ajhp070369>

Zhou, Z., Rahme, E., Abrahamowicz, M., & Pilote, L. (2005). Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods. *American Journal of Epidemiology*, 162(10), 1016–1023. <https://doi.org/10.1093/aje/kwi307>

5.3 - Methods to address bias

Ali, Ms. et al. (2014). Propensity Score Balance Measures in Pharmacoepidemiology: A Simulation Study. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3574>

Ali, Ms. et al. (2015). Reporting of Covariate Selection and Balance Assessment in Propensity Score Analysis Is Suboptimal: A Systematic Review. *Journal of Clinical Epidemiology*. <https://doi.org/10.1016/j.jclinepi.2014.08.011>

Arbogast, P. G., & Ray, W. A. (2009). Use of disease risk scores in pharmacoepidemiologic studies. *Statistical Methods in Medical Research*, 18(1), 67–80. <https://doi.org/10.1177/0962280208092347>

Baiocchi, M. et al. (2014). Instrumental Variable Methods for Causal Inference. *Statistics in Medicine*. <https://doi.org/10.1002/sim.6128>

Belitser, Sv. et al. (2011). Measuring Balance and Model Selection in Propensity Score Methods. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.2188>

Bernal, J. L., Cummins, S., & Gasparrini, A. (2017). Interrupted time series regression for the evaluation of public health interventions: a tutorial. *International Journal of Epidemiology*, 46(1), 348–355. <https://doi.org/10.1093/ije/dyw098>

Brenner, H., & Gefeller, O. (1993). Use of the Positive Predictive Value to Correct for Disease Misclassification in Epidemiologic Studies. *American Journal of Epidemiology*, 138(11), 1007–1015. <https://doi.org/10.1093/oxfordjournals.aje.a116805>

Brookhart, M. A., Rassen, J. A., & Schneeweiss, S. (2010). Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidemiology and Drug Safety*, 19(6), 537–554. <https://doi.org/10.1002/pds.1908>

Brookhart, M. A., Wang, P., Solomon, D. H., & Schneeweiss, S. (2006). Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. *Epidemiology (Cambridge, Mass.)*, 17(3), 268–275. <https://doi.org/10.1097/01.ede.0000193606.58671.c5>

Cole, Sr. et al. (2003). Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death Using Marginal Structural Models. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwg206>

- Daniel, Rm. et al. (2013). Methods for Dealing With Time-Dependent Confounding. *Statistics in Medicine*. <https://doi.org/10.1002/sim.5686>
- Dormuth, Cr. et al. (2009). Statin Adherence and Risk of Accidents: A Cautionary Tale. *Circulation*. <https://doi.org/10.1161/CIRCULATIONAHA.108.824151>
- Dusetzina, Sb. et al. (2015). Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. *Health Services Research*. <https://doi.org/10.1111/1475-6773.12279>
- Farrington, Cp. et al. (2009). Case Series Analysis for Censored, Perturbed, or Curtailed Post-Event Exposures. *Biostatistics (Oxford, England)*. <https://doi.org/10.1093/biostatistics/kxn013>
- Franklin, Jm. et al. (2014). Metrics for Covariate Balance in Cohort Studies of Causal Effects. *Statistics in Medicine*. <https://doi.org/10.1002/sim.6058>
- Garabedian, Lf. et al. (2014). Potential Bias of Instrumental Variable Analyses for Observational Comparative Effectiveness Research. *Annals of Internal Medicine*. <https://doi.org/10.7326/M13-1887>
- Glynn, Rj. et al. (2012). Role of Disease Risk Scores in Comparative Effectiveness Research With Emerging Therapies. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3231>
- Greenland, S. (1996a). Confounding and Exposure Trends in Case-Crossover and Case-Time-Control Designs. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/00001648-199605000-00003>
- Greenland, S. (1996b). Basic Methods for Sensitivity Analysis of Biases. *International Journal of Epidemiology*. <https://pubmed.ncbi.nlm.nih.gov/9027513/>
- Greenland, S. (2000). An introduction to instrumental variables for epidemiologists. *International Journal of Epidemiology*, 29(4), 722–729. <https://doi.org/10.1093/ije/29.4.722>
- Groenwold, Rh. et al. (2011). Balance Measures for Propensity Score Methods: A Clinical Example on Beta-Agonist Use and the Risk of Myocardial Infarction. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.2251>
- Hallas, J. (1996). Evidence of Depression Provoked by Cardiovascular Medication: A Prescription Sequence Symmetry Analysis. *Epidemiology (Cambridge, Mass.)*. <https://pubmed.ncbi.nlm.nih.gov/8862977/>
- Hallas, J. et al. (2014). Use of Self-Controlled Designs in Pharmacoepidemiology. *Journal of Internal Medicine*. <https://doi.org/10.1111/joim.12186>
- Hallas, J. et al. (2016). Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kww079>
- Hauben, M. et al. (2016). Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP). *Drug Safety*. <https://doi.org/10.1007/s40264-016-0392-2>
- Hernán, M. A. (2018). The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data. *American Journal of Public Health*, 108(5), 616–619. <https://doi.org/10.2105/AJPH.2018.304337>
- Hernán, Ma. et al. (2000). Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-positive Men. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/00001648-200009000-00012>

- Hernán, Ma. et al. (2016). Specifying a Target Trial Prevents Immortal Time Bias and Other Self-Inflicted Injuries in Observational Analyses. *Journal of Clinical Epidemiology*.
<https://doi.org/10.1016/j.jclinepi.2016.04.014>
- Hernán, Ma. et al. (2016). Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwv254>
- Hernán, Ma. et al. (2018). How to Estimate the Effect of Treatment Duration on Survival Outcomes Using Observational Data. *BMJ (Clinical Research Ed.)*. <https://doi.org/10.1136/bmj.k182>
- Joffe, Mm. et al. (1999). Invited Commentary: Propensity Scores. *American Journal of Epidemiology*.
<https://doi.org/10.1093/oxfordjournals.aje.a010011>
- Jurek, Am. (2005). Proper Interpretation of Non-Differential Misclassification Effects: Expectations vs Observations. *International Journal of Epidemiology*. <https://doi.org/10.1093/ije/dyi060>
- Kontopantelis, E., Doran, T., Springate, D. A., Buchan, I., & Reeves, D. (2015). Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. *The BMJ*, 350. <https://doi.org/10.1136/bmj.h2750>
- Lash, Tl. et al. (2014). Good Practices for Quantitative Bias Analysis. *International Journal of Epidemiology*. <https://doi.org/10.1093/ije/dyu149>
- Lawlor, Da. et al. (2016). Triangulation in Aetiological Epidemiology. *International Journal of Epidemiology*. <https://doi.org/10.1093/ije/dyw314>
- Lund, Jl. et al. (2015). The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. *Current Epidemiology Reports*.
<https://doi.org/10.1007/s40471-015-0053-5>
- Maclure, M. et al. (1991). The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. *American Journal of Epidemiology*.
<https://doi.org/10.1093/oxfordjournals.aje.a115853>
- Maclure, Ma. et al. (2012). When Should Case-Only Designs Be Used for Safety Monitoring of Medical Products? *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.2330>
- Martens, Ep. et al. (2006). Instrumental Variables: Application and Limitations. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/01.ede.0000215160.88317.cb>
- Miettinen, O. S. (1976). Stratification by a multivariate confounder score. *American Journal of Epidemiology*, 104(6), 609–620. <https://doi.org/10.1093/oxfordjournals.aje.a112339>
- Miettinen, Os. et al. (1989). The Clinical Trial as a Paradigm for Epidemiologic Research. *Journal of Clinical Epidemiology*. [https://doi.org/10.1016/0895-4356\(89\)90143-1](https://doi.org/10.1016/0895-4356(89)90143-1)
- Nicholas, Jm. et al. (2012). Within-person Study Designs Had Lower Precision and Greater Susceptibility to Bias Because of Trends in Exposure Than Cohort and Nested Case-Control Designs. *Journal of Clinical Epidemiology*. <https://doi.org/10.1016/j.jclinepi.2011.09.004>
- Outcome Misclassification. (n.d.). Retrieved 3 July 2020, from <https://apps.p-95.com/ISPE/>
- Rassen, J. A., & Schneeweiss, S. (2012a). Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. *Pharmacoepidemiology and Drug Safety*, 21(S1), 41–49. <https://doi.org/10.1002/pds.2328>

- Rassen, J. A., Glynn, R. J., Brookhart, M. A., & Schneeweiss, S. (2011). Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. *American Journal of Epidemiology*, 173(12), 1404–1413. <https://doi.org/10.1093/aje/kwr001>
- Rassen, Ja. et al. (2012). Newly Marketed Medications Present Unique Challenges for Nonrandomized Comparative Effectiveness Analyses. *Journal of Comparative Effectiveness Research*. <https://doi.org/10.2217/ceer.12.12>
- Rassen, Ja. et al. (2012). One-to-many Propensity Score Matching in Cohort Studies. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3263>
- Rassen, Ja. et al. (2013). Matching by Propensity Score in Cohort Studies With Three Treatment Groups. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/EDE.0b013e318289dedf>
- Ray, W. A. (2003). Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. *American Journal of Epidemiology*, 158(9), 915–920. <https://doi.org/10.1093/aje/kwg231>
- Robins, Jm. et al. (2000). Marginal Structural Models and Causal Inference in Epidemiology. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/00001648-200009000-00011>
- Sanni Ali, M. et al. (2013). Time-dependent Propensity Score and Collider-Stratification Bias: An Example of beta2-agonist Use and the Risk of Coronary Heart Disease. *European Journal of Epidemiology*. <https://doi.org/10.1007/s10654-013-9766-2>
- Schmidt, Af. Et al. (2016). Adjusting for Confounding in Early Postlaunch Settings: Going Beyond Logistic Regression Models. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/EDE.0000000000000388>
- Schneeweiss, S. (2018). Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. *Clinical Epidemiology*, 10, 771–788. <https://doi.org/10.2147/CLEP.S166545>
- Schneeweiss, S. et al. (2009). High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/EDE.0b013e3181a663cc>
- Schneeweiss, S. et al. (2011). Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development. *Clinical Pharmacology and Therapeutics*. <https://doi.org/10.1038/clpt.2011.235>
- Schuemie, Mj. et al. (2014, January 30). Interpreting Observational Studies: Why Empirical Calibration Is Needed to Correct P-Values. *Statistics in Medicine*. <https://doi.org/10.1002/sim.5925>
- Schuemie, Mj. et al. (2016). Robust Empirical Calibration of P-Values Using Observational Data. *Statistics in Medicine*. <https://doi.org/10.1002/sim.6977>
- Schuemie, Mj. et al. (2018). Empirical Confidence Interval Calibration for Population-Level Effect Estimation Studies in Observational Healthcare Data. *Proceedings of the National Academy of Sciences of the United States of America*. <https://doi.org/10.1073/pnas.1708282114>
- Shrank, Wh. et al. (2011). Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians. *Journal of General Internal Medicine*. <https://doi.org/10.1007/s11606-010-1609-1>
- Stürmer, T. et al. (2007). Performance of Propensity Score Calibration--A Simulation Study. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwm074>

Stürmer, T. et al. (2010). Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwq198>

Suchard, Ma. et al. (2013). Empirical Performance of the Self-Controlled Case Series Design: Lessons for Developing a Risk Identification and Analysis System. *Drug Safety*. <https://doi.org/10.1007/s40264-013-0100-4>

Suissa, S. (1995). The Case-Time-Control Design. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/https://www.ncbi.nlm.nih.gov/pubmed/7619931>

Suissa, S. et al. (2017). Prevalent New-User Cohort Designs for Comparative Drug Effect Studies by Time-Conditional Propensity Scores. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.4107>

Sujan, Ac. et al. (2017). Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. *JAMA*. <https://doi.org/10.1001/jama.2017.3413>

Swanson, S. A., Robins, J. M., Miller, M., & Hernán, M. A. (2015). Selecting on Treatment: A Pervasive Form of Bias in Instrumental Variable Analyses. *American Journal of Epidemiology*, 181(3), 191–197. <https://doi.org/10.1093/aje/kwu284>

Swanson, Sa. et al. (2013). Commentary: How to Report Instrumental Variable Analyses (Suggestions Welcome). *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/EDE.0b013e31828d0590>

Tadrous, M., Gagne, J. J., Stürmer, T., & Cadarette, S. M. (2013). Disease Risk Score (DRS) as a Confounder Summary Method: Systematic Review and Recommendations. *Pharmacoepidemiology and Drug Safety*, 22(2), 122–129. <https://doi.org/10.1002/pds.3377>

Tannen, R. L., Weiner, M. G., & Xie, D. (2008). Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication. *Pharmacoepidemiology and Drug Safety*, 17(7), 671–685. <https://doi.org/10.1002/pds.1584>

Toh, S. et al. (2011). Confounding Adjustment via a Semi-Automated High-Dimensional Propensity Score Algorithm: An Application to Electronic Medical Records. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.2152>

Uddin, M. J., Groenwold, R. H. H., de Boer, A., Afonso, A. S. M., Primatesta, P., Becker, C., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and Drug Safety*, 25(S1), 132–141. <https://doi.org/10.1002/pds.3860>

Uddin, M. J., Groenwold, R. H. H., van Staa, T. P., de Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2015). Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. *Pharmacoepidemiology and Drug Safety*, 24(5), 468–477. <https://doi.org/10.1002/pds.3724>

Uddin, Mj. et al. (2014). Performance of Instrumental Variable Methods in Cohort and Nested Case-Control Studies: A Simulation Study. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3555>

Wang, S. et al. (2011). Future Cases as Present Controls to Adjust for Exposure Trend Bias in Case-Only Studies. *Epidemiology (Cambridge, Mass.)*. <https://doi.org/10.1097/EDE.0b013e31821d09cd>

Weldeselassie, Yg. et al. (2011). Use of the Self-Controlled Case-Series Method in Vaccine Safety Studies: Review and Recommendations for Best Practice. *Epidemiology and Infection*. <https://doi.org/10.1017/S0950268811001531>

Whitaker, Hj. et al. (2006). Tutorial in Biostatistics: The Self-Controlled Case Series Method. *Statistics in Medicine*. <https://doi.org/10.1002/sim.2302>

Williamson, E. et al. (2012). Propensity Scores: From Naive Enthusiasm to Intuitive Understanding. *Statistical Methods in Medical Research*. <https://doi.org/10.1177/0962280210394483>

Witteaman, Jc. et al. (1998). G-estimation of Causal Effects: Isolated Systolic Hypertension and Cardiovascular Death in the Framingham Heart Study. *American Journal of Epidemiology*. <https://doi.org/10.1093/oxfordjournals.aje.a009658>

Xinyao, Ji. et al. (2017). The Trend-in-trend Research Design for Causal Inference. *Epidemiology (Cambridge, Mass.)*, 28(4), 529–536. <https://doi.org/10.1097/EDE.0000000000000579>

Xu, S. et al. (2011). Identifying Optimal Risk Windows for Self-Controlled Case Series Studies of Vaccine Safety. *Statistics in Medicine*. <https://doi.org/10.1002/sim.4125>

5.4 - Effect measure modification and interaction

Altman, D. G., & Bland, J. M. (2003). Interaction revisited: the difference between two estimates. *BMJ (Clinical Research Ed.)*, 326(7382), 219. <https://doi.org/10.1136/bmj.326.7382.219>

Knol, M. J., & VanderWeele, T. J. (2012). Recommendations for presenting analyses of effect modification and interaction. *International Journal of Epidemiology*, 41(2), 514–520. <https://doi.org/10.1093/ije/dyr218>

Knol, M. J., VanderWeele, T. J., Groenwold, R. H. H., Klungel, O. H., Rovers, M. M., & Grobbee, D. E. (2011). Estimating measures of interaction on an additive scale for preventive exposures. *European Journal of Epidemiology*, 26(6), 433–438.

Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., Altman, D. G., & Consolidated Standards of Reporting Trials Group. (2010). CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *Journal of Clinical Epidemiology*, 63(8), e1-37. <https://doi.org/10.1016/j.jclinepi.2010.03.004>

Moride, Y., Abenhaim, L., Yola, M., & Lucein, A. (1994). Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. *Journal of Clinical Epidemiology*, 47(7), 731–737. [https://doi.org/10.1016/0895-4356\(94\)90170-8](https://doi.org/10.1016/0895-4356(94)90170-8)

Schmidt, A. et al. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. (2014). *Journal of Clinical Epidemiology*, 67(7), 821–829. <https://doi.org/10.1016/j.jclinepi.2014.02.008>

Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & STROBE Initiative. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology (Cambridge, Mass.)*, 18(6), 805–835. <https://doi.org/10.1097/EDE.0b013e3181577511>

VanderWeele, T. J. (2009). On the distinction between interaction and effect modification. *Epidemiology (Cambridge, Mass.)*, 20(6), 863–871. <https://doi.org/10.1097/EDE.0b013e3181ba333c>

5.5 - Ecological analyses and case-population studies

Farrington, Cp. (2004). Control Without Separate Controls: Evaluation of Vaccine Safety Using Case-Only Methods. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2004.01.017>

Gulmez, S. E., Larrey, D., Pageaux, G.-P., Lignot, S., Lassalle, R., Jové, J., Gatta, A., McCormick, P. A., Metselaar, H. J., Monteiro, E., Thorburn, D., Bernal, W., Zouboulis-Vafiadis, I., Vries, C. de, Perez-Gutthann, S., Sturkenboom, M., Bénichou, J., Montastruc, J.-L., Horsmans, Y., ... Moore, N. (2013). Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen). *Drug Safety*, 36(2), 135–144. <https://doi.org/10.1007/s40264-012-0013-7>

Moore, N., Gulmez, S. E., Larrey, D., Pageaux, G.-P., Lignot, S., Lassalle, R., Jové, J., Pariente, A., Blin, P., Bénichou, J., & Bégaud, B. (2013). Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. *Pharmacoepidemiology and Drug Safety*, 22(2), 160–167. <https://doi.org/10.1002/pds.3371>

Théophile, H., Laporte, J.-R., Moore, N., Martin, K.-L., & Bégaud, B. (2011). The Case-Population Study Design. *Drug Safety*, 34(10), 861–868. <https://doi.org/10.2165/11592140-000000000-00000>

5.6 - Pragmatic trials and large simple trials

Collier, S., Harvey, C., Brewster, J., Bakerly, N. D., Elkhenini, H. F., Stanciu, R., Williams, C., Breerton, J., New, J. P., McCrae, J., McCorkindale, S., & Leather, D. (2016). Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study. *Pharmacoepidemiology and Drug Safety*, 26(3), 344–352. <https://doi.org/10.1002/pds.4118>

Fröbert, O., Lagerqvist, B., Olivecrona, G. K., Omerovic, E., Gudnason, T., Maeng, M., Aasa, M., Angerås, O., Calais, F., Danielewicz, M., Erlinge, D., Hellsten, L., Jensen, U., Johansson, A. C., Kåregren, A., Nilsson, J., Robertson, L., Sandhall, L., Sjögren, I., ... James, S. K. (2013). Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. *The New England Journal of Medicine*. <https://doi.org/10.1056/NEJMoa1308789>

IMI GetReal Project - Glossary of Definitions of Common Terms. (n.d.). Retrieved 18 May 2020, from https://www.imi-getreal.eu/Portals/1/Documents/01%20deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf

Lauer, M. S., & D'Agostino, R. B. S. (2013). The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research? *The New England Journal of Medicine*. <https://doi.org/10.1056/NEJMp1310102>

Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015). The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ*, 350. <https://doi.org/10.1136/bmj.h2147>

Collins, R. et al. (2020). The Magic of Randomization Versus the Myth of Real-World Evidence. *The New England Journal of Medicine*. <https://doi.org/10.1056/NEJMs1901642>

Lesko, Sm. et al. (1995). An Assessment of the Safety of Pediatric Ibuprofen. A Practitioner-Based Randomized Clinical Trial. *JAMA*. <https://pubmed.ncbi.nlm.nih.gov/7884951/>

Rao, S. et al. A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial. (2014). *JACC: Cardiovascular Interventions*, 7(8), 857–867. <https://doi.org/10.1016/j.jcin.2014.04.007>

Staa, T.-P. van, Goldacre, B., Gulliford, M., Cassell, J., Pirmohamed, M., Taweel, A., Delaney, B., & Smeeth, L. (2012). Pragmatic randomised trials using routine electronic health records: putting them to the test. *BMJ*, 344. <https://doi.org/10.1136/bmj.e55>

Strom, B. L., Eng, S. M., Faich, G., Reynolds, R. F., D'Agostino, R. B., Ruskin, J., & Kane, J. M. (2011). Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). *American Journal of Psychiatry*, 168(2), 193–201. <https://doi.org/10.1176/appi.ajp.2010.08040484>

Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., & Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *CMAJ*, 180(10), E47–E57. <https://doi.org/10.1503/cmaj.090523>

Van Staa, T-P. (2014). The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. *Health Technology Assessment*, 18(43). <https://doi.org/10.3310/hta18430>

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., & Moher, D. (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*, 337. <https://doi.org/10.1136/bmj.a2390>

5.7 – Systematic reviews and meta-analysis

Chou, R., & Helfand, M. (2005). Challenges in Systematic Reviews That Assess Treatment Harms. *Annals of Internal Medicine*, 142(12_Part_2), 1090–1099. https://doi.org/10.7326/0003-4819-142-12_Part_2-200506211-00009

CIOMS Working Group X - Guideline on Evidence Synthesis and Meta-Analysis for Drug Safety. (n.d.). COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES - CIOMS. Retrieved 26 May 2020, from https://cioms.ch/working_groups/working-group-x/

Henry, D., Lim, L. L.-Y., Rodriguez, L. A. G., Gutthann, S. P., Carson, J. L., Griffin, M., Savage, R., Logan, R., Moride, Y., Hawkey, C., Hill, S., & Fries, J. T. (1996). Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. *BMJ*, 312(7046), 1563–1566. <https://doi.org/10.1136/bmj.312.7046.1563>

5.8 – Signal detection methodology and application

Wisniewski, Af. et al. (2016, June). Good Signal Detection Practices: Evidence From IMI PROTECT. *Drug Safety*. <https://doi.org/10.1007/s40264-016-0405-1>

Guideline on good pharmacovigilance practices (GVP) Module IX – Signal management (Rev 1) European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiology and Drug Safety*, 18(6), 427–436. <https://doi.org/10.1002/pds.1742>

Berlin, C., Blanch, C., Lewis, D. J., Maladorno, D. D., Michel, C., Petrin, M., Sarp, S., & Close, P. (2012). Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. *Pharmacoepidemiology and Drug Safety*, 21(6), 622–630. <https://doi.org/10.1002/pds.2247>

Candore, G., Juhlin, K., Manlik, K., Thakrar, B., Quarcoo, N., Seabroke, S., Wisniewski, A., & Slattery, J. (2015). Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases. *Drug Safety*, 38(6), 577–587. <https://doi.org/10.1007/s40264-015-0289-5>

- Caster, O., Juhlin, K., Watson, S., & Norén, G. N. (2014). Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in *vigiRank*. *Drug Safety*, 37(8), 617–628. <https://doi.org/10.1007/s40264-014-0204-5>
- Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2010). Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database. *Statistical Analysis and Data Mining: The ASA Data Science Journal*, 3(4), 197–208. <https://doi.org/10.1002/sam.10078>
- Caster, O., Norén, G. N., Madigan, D., & Bate, A. (2013). Logistic Regression in Signal Detection: Another Piece Added to the Puzzle. *Clinical Pharmacology & Therapeutics*, 94(3), 312–312. <https://doi.org/10.1038/clpt.2013.107>
- DuMouchel, W., Yuen, N., Payvandi, N., Booth, W., Rut, A., & Fram, D. (2013). Automated Method for Detecting Increases in Frequency of Spontaneous Adverse Event Reports over Time. *Journal of Biopharmaceutical Statistics*, 23(1), 161–177. <https://doi.org/10.1080/10543406.2013.736809>
- Salvo, F. (2013). A Potential Event-Competition Bias in Safety Signal Detection: Results From a Spontaneous Reporting Research Database in France. *Drug Safety*. <https://doi.org/10.1007/s40264-013-0063-5>
- Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H. (2013). Performance of Pharmacovigilance Signal Detection Algorithms for the FDA Adverse Event Reporting System. *Clinical Pharmacology and Therapeutics*, 93(6). <https://doi.org/10.1038/clpt.2013.24>
- Hauben, M., Madigan, D., Gerrits, C. M., Walsh, L., & Puijenbroek, E. P. V. (2005). The role of data mining in pharmacovigilance. *Expert Opinion on Drug Safety*, 4(5), 929–948. <https://doi.org/10.1517/14740338.4.5.929>
- Holle, L. V., & Bauchau, V. (2014). Use of Logistic Regression to Combine Two Causality Criteria for Signal Detection in Vaccine Spontaneous Report Data. *Drug Safety*, 37(12), 1047–1057. <https://doi.org/10.1007/s40264-014-0237-9>
- Juhlin, K., Karimi, G., Andér, M., Camilli, S., Dheda, M., Har, T. S., Isahak, R., Lee, S.-J., Vaughan, S., Caduff, P., & Norén, G. N. (2015). Using *VigiBase* to Identify Substandard Medicines: Detection Capacity and Key Prerequisites. *Drug Safety*, 38(4), 373–382. <https://doi.org/10.1007/s40264-015-0271-2>
- Juhlin, K. (2013). Outlier Removal to Uncover Patterns in Adverse Drug Reaction Surveillance - A Simple Unmasking Strategy. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3474>
- Low, Y. S., Caster, O., Bergvall, T., Fourches, D., Zang, X., Norén, G. N., Rusyn, I., Edwards, R., & Tropsha, A. (2016). Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome. *Journal of the American Medical Informatics Association*, 23(5), 968–978. <https://doi.org/10.1093/jamia/ocv127>
- Maignen, F., Hauben, M., Hung, E., Holle, L. V., & Dogne, J.-M. (2014). A conceptual approach to the masking effect of measures of disproportionality. *Pharmacoepidemiology and Drug Safety*, 23(2), 208–217. <https://doi.org/10.1002/pds.3530>
- Maignen, F., Hauben, M., Hung, E., Van Holle, L., & Dogne, J.-M. (2014). Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. *Pharmacoepidemiology and Drug Safety*, 23(2), 195–207. <https://doi.org/10.1002/pds.3529>

MedDRA - Medical Dictionary for Regulatory Activities. (n.d.). Retrieved 27 May 2020, from <https://www.meddra.org/>

Norén, G. N., & Edwards, I. R. (2009). Modern methods of pharmacovigilance: detecting adverse effects of drugs. *Clinical Medicine*, 9(5), 486–489. <https://doi.org/10.7861/clinmedicine.9-5-486>

OHDSI – Observational Health Data Sciences and Informatics. (n.d.). Retrieved 23 June 2020, from <https://www.ohdsi.org/>

OMOP Common Data Model – OHDSI. (n.d.). Retrieved 23 June 2020, from <https://www.ohdsi.org/data-standardization/the-common-data-model/>

Pinheiro, L. C., Candore, G., Zaccaria, C., Slattery, J., & Arlett, P. (2018). An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance.

Pharmacoepidemiology and Drug Safety, 27(1), 38–45. <https://doi.org/10.1002/pds.4344>

Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. (n.d.). COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. Retrieved 26 May 2020, from <https://cioms.ch/publications/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/>

PROTECT. Retrieved 27 May 2020, from <http://www.imi-protect.eu/about.shtml>

PROTECT - Database of adverse drug reactions listed in the SPC of centrally authorised medicinal products. (n.d.). Retrieved 27 May 2020, from <http://www.imi-protect.eu/methodsRep.shtml>

FDA's Sentinel Initiative. FDA. <https://www.fda.gov/safety/fdas-sentinel-initiative>

FDA's Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. U.S. Food and Drug Administration. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment>

Scholl, J. H. G., van Hunsel, F. P. A. M., Hak, E., & van Puijenbroek, E. P. (2018). A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. *Pharmacoepidemiology and Drug Safety*, 27(2), 199–205. <https://doi.org/10.1002/pds.4364>

Screening for adverse reactions in EudraVigilance. (n.d.). Retrieved 26 May 2020, from https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf

Seabroke, S., Candore, G., Juhlin, K., Quarcoo, N., Wisniewski, A., Arani, R., Painter, J., Tregunno, P., Norén, G. N., & Slattery, J. (2016). Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases. *Drug Safety*, 39(4), 355–364. <https://doi.org/10.1007/s40264-015-0388-3>

Stephenson, W. P., & Hauben, M. (2007). Data mining for signals in spontaneous reporting databases: proceed with caution. *Pharmacoepidemiology and Drug Safety*, 16(4), 359–365. <https://doi.org/10.1002/pds.1323>

Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012). Data-Driven Prediction of Drug Effects and Interactions. *Science Translational Medicine*, 4(125), 125ra31-125ra31. <https://doi.org/10.1126/scitranslmed.3003377>

Harpaz, R. et al. (2017). Toward Multimodal Signal Detection of Adverse Drug Reactions. *Journal of Biomedical Informatics*. <https://doi.org/10.1016/j.jbi.2017.10.013>

5.9 - Methods for pharmacovigilance impact research

No references.

Chapter 6 – The statistical analysis plan

ICH E9 statistical principles for clinical trials [Text]. European Medicines Agency. Retrieved 28 May 2020, from <https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials>

Welch, Ca. et al. (2014). Evaluation of Two-Fold Fully Conditional Specification Multiple Imputation for Longitudinal Electronic Health Record Data. *Statistics in Medicine*. <https://doi.org/10.1002/sim.6184>

Gail MH, Benichou J. (2000). *Encyclopedia of Epidemiologic Methods* (2000th ed.). Wiley.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH. Retrieved 28 May 2020, from <https://www.ich.org/>

ICH E9(R1) - Addendum on estimands and sensitivity analysis in clinical trials. (n.d.). Retrieved 11 June 2020, from https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf

Jones, M. P. (1996). Indicator and Stratification Methods for Missing Explanatory Variables in Multiple Linear Regression. *Journal of the American Statistical Association*, 91(433), 222–230. JSTOR. <https://doi.org/10.2307/2291399>

Lee, Kj., Carlin, Jb. (2012). Recovery of Information From Multiple Imputation: A Simulation Study. *Emerging Themes in Epidemiology*. <https://doi.org/10.1186/1742-7622-9-3>

Little RJA, Rubin DB. (2002). *Statistical analysis with missing data* (2nd ed.). Wiley.

Moons, K. et al. Using the outcome for imputation of missing predictor values was preferred. (2006). *Journal of Clinical Epidemiology*, 59(10), 1092–1101. <https://doi.org/10.1016/j.jclinepi.2006.01.009>

Rosenbaum, P. R. (2010). *Design of Observational Studies*. Springer.

Rothman K, Greenland S, Lash T. (2008). *Modern Epidemiology* (3rd ed.). Lippincott Williams & Wilkins.

Rubin DB. (2004). *Multiple Imputation for Nonresponse in Surveys*. Wiley.

Schafer JL. (1997). *Analysis of Incomplete Multivariate Data*. Chapman & Hall.

Chapter 7 – Quality management

AHSC's Quality Control and Quality Assurance SOP. (n.d.). Retrieved 28 May 2020, from https://www.imperial.ac.uk/media/imperial-college/research-and-innovation/joint-research-compliance-office/public/JRCO_SOP_025_QAQC_V7.0_25Oct2017.pdf

Guideline on good pharmacovigilance practices (GVP) Module I – Pharmacovigilance systems and their quality systems. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Commission Implementing Regulation (EU) No 520/2012. (n.d.). <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Whitney, Cw. et al. (1998). Quality Assurance and Quality Control in Longitudinal Studies. *Epidemiologic Reviews*. <https://doi.org/10.1093/oxfordjournals.epirev.a017973>

Herrett, E. et al. (2010). Validation and Validity of Diagnoses in the General Practice Research Database: A Systematic Review. *British Journal of Clinical Pharmacology*.
<https://doi.org/10.1111/j.1365-2125.2009.03537.x>

EURODURG - International Society for Pharmacoepidemiology. (n.d.). Retrieved 29 May 2020, from
<https://www.pharmacoepi.org/eurodurg/>

European Forum for Good Clinical Practice (EFGCP) Guidelines. (n.d.).
<http://www.efgcp.eu/Publications.asp?Type=EFGCP%20publications&L1=13&L2=1>

Furu, K. (2008). Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. *Norsk Epidemiologi*, 18(2).
<https://doi.org/10.5324/nje.v18i2.23>

Guidelines for Quality Assurance in Multicenter Trials: A Position Paper. (1998). *Controlled Clinical Trials*, 19(5), 477–493. [https://doi.org/10.1016/S0197-2456\(98\)00033-6](https://doi.org/10.1016/S0197-2456(98)00033-6)

Hoffmann, W., Latza, U., Baumeister, S. E., Brünger, M., Buttman-Schweiger, N., Hardt, J., Hoffmann, V., Karch, A., Richter, A., Schmidt, C. O., Schmidtman, I., Swart, E., & Berg, N. van den. (2019). Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology. *European Journal of Epidemiology*, 34(3), 301–317. <https://doi.org/10.1007/s10654-019-00500-x>

ICH E6 (R2) Good clinical practice. (n.d.). Retrieved 10 June 2020, from
<https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice>

ICH E8 (R1) General considerations for clinical studies. (2018, September 17). European Medicines Agency. <https://www.ema.europa.eu/en/ich-e8-general-considerations-clinical-studies>

ISO 9000:2015 - Quality management systems — Fundamentals and vocabulary. (n.d.). ISO. Retrieved 28 May 2020, from
<https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standard/04/54/45481.html>

ISO Quality management principles. (n.d.). Retrieved 28 May 2020, from
<https://www.iso.org/files/live/sites/isoorg/files/store/en/PUB100080.pdf>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (2015). International Society for Pharmacoepidemiology. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Hoven, JI. et al. (2005). Indicators of Prescribing Quality in Drug Utilisation Research: Report of a European Meeting (DURQUIM, 13-15 May 2004). *European Journal of Clinical Pharmacology*.
<https://doi.org/10.1007/s00228-004-0845-x>

Kiran, D. R. (2016). *Total Quality Management - 1st Edition (1st ed.)*. BSP Books, Elsevier.
<https://www.elsevier.com/books/total-quality-management/kiran/978-0-12-811035-5>

Blomgren, Kj. et al. (2006). Interviewer Variability - Quality Aspects in a Case-Control Study. *European Journal of Epidemiology*. <https://doi.org/10.1007/s10654-006-0017-7>

Reppe, La. et al. (2017). Quality Assessment of Structure and Language Elements of Written Responses Given by Seven Scandinavian Drug Information Centres. *European Journal of Clinical Pharmacology*. <https://doi.org/10.1007/s00228-017-2209-3>

Reisch, Lm. et al. (2003). Training, Quality Assurance, and Assessment of Medical Record Abstraction in a Multisite Study. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwg016>

Lindquist, M. (2004). Data Quality Management in Pharmacovigilance. Drug Safety.
<https://doi.org/10.2165/00002018-200427120-00003>

McGraw, M. J., George, A. N., Shearn, S. P., Jr, T. F. H., & Hall, R. L. (2010). Principles of Good Clinical Practice. Pharmaceutical Press.

Alzoubi, Mm. et al. (2019). Total Quality Management in the Health-Care Context: Integrating the Literature and Directing Future Research. Risk Management and Healthcare Policy.
<https://doi.org/10.2147/RMHP.S197038>

Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition Addendum (Overview) | Effective Health Care Program. (n.d.). Agency for Healthcare Research and Quality. Retrieved 29 May 2020, from <https://effectivehealthcare.ahrq.gov/products/registries-guide-3rd-edition-addendum/overview>

Research, C. for D. E. and. (2013, May). FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. U.S. Food and Drug Administration. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

Sprenger, K., Nickerson, D., Meeker-O'Connell, A., & Morrison, B. W. (2013). Quality by Design in Clinical Trials: A Collaborative Pilot With FDA. Therapeutic Innovation & Regulatory Science, 47(2), 161–166. <https://doi.org/10.1177/0092861512458909>

Theobald, K., Capan, M., Herbold, M., Schinzel, S., & Hundt, F. (2009). Quality assurance in non-interventional studies. GMS German Medical Science, 7. <https://doi.org/10.3205/000088>

Chapter 8 – Dissemination and communication of study results

Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

ENCePP Checklist for Study Protocols. (n.d.). ENCePP. Retrieved 11 June 2020, from http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml

ENCePP Code of Conduct. (n.d.). ENCePP. Retrieved 11 June 2020, from http://www.encepp.eu/code_of_conduct/index.shtml

Enhancing the QUALity and Transparency Of Health Research - EQUATOR Network. (n.d.). EQUATOR Network. Retrieved 11 June 2020, from <https://www.equator-network.org/>

EU PAS Register. (n.d.). ENCePP. Retrieved 11 June 2020, from http://www.encepp.eu/encepp_studies/indexRegister.shtml

FDA. (2013). FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. FDA. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic>

GRACE Principles - Good ReseArch for Comparative Effectiveness. (n.d.). GRACE - Good ReseArch for Comparative Effectiveness. Retrieved 11 June 2020, from <https://www.graceprinciples.org/>

Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies - EMA. (n.d.). Retrieved 11 June 2020, from https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies - EMA. (n.d.). Retrieved 11 June 2020, from https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf

Simera, I. et al. (2010). A Catalogue of Reporting Guidelines for Health Research. European Journal of Clinical Investigation. <https://doi.org/10.1111/j.1365-2362.2009.02234.x>

ICMJE - International Committee of Medical Journal Editors. (n.d.). International Committee of Medical Journal Editors. Retrieved 11 June 2020, from <http://www.icmje.org/>

ICMJE - Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. (n.d.). International Committee of Medical Journal Editors. Retrieved 11 June 2020, from <http://www.icmje.org/recommendations/>

IEA Publications - Good Epidemiology Practices - GEP (2007). (n.d.). IEA - International Epidemiological Association. Retrieved 11 June 2020, from https://ieaweb.org/IEAWeb/Content/IEA_Publications.aspx

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). (2015). International Society for Pharmacoepidemiology (ISPE). <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Cohen, Jf. et al. (2016). STARD 2015 Guidelines for Reporting Diagnostic Accuracy Studies: Explanation and Elaboration. BMJ Open. <https://doi.org/10.1136/bmjopen-2016-012799>

Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Fillion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., Guttman, A., Harron, K., Hemkens, L. G., Moher, D., Schneeweiss, S., Smeeth, L., Sturkenboom, M., Elm, E. von, Wang, S. V., & Benchimol, E. I. (2018). RECORD-PE statement - The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology. BMJ, 363. <https://doi.org/10.1136/bmj.k3532>

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339. <https://doi.org/10.1136/bmj.b2535>

Nicholls, S. G., Quach, P., Elm, E. von, Guttman, A., Moher, D., Petersen, I., Sørensen, H. T., Smeeth, L., Langan, S. M., & Benchimol, E. I. (2015). The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines. PLOS ONE, 10(5), e0125620. <https://doi.org/10.1371/journal.pone.0125620>

Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ, 340. <https://doi.org/10.1136/bmj.c332>

STROBE - Strengthening the Reporting of Observational studies in Epidemiology Statement Guidelines for reporting observational studies. (n.d.). STROBE. Retrieved 11 June 2020, from <https://strobe-statement.org/index.php?id=strobe-publications>

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., Thacker, S. B., & Epidemiology (MOOSE)

Stroup, Df. et al. (2000). Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA, 283(15), 2008–2012. <https://doi.org/10.1001/jama.283.15.2008>

Wang, Sv. et al. (2017). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and Drug Safety. <https://doi.org/10.1002/pds.4295>

WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. (2018). <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

Kelly, Wn. et al. (2007). Guidelines for Submitting Adverse Event Reports for Publication. Pharmacoepidemiology and Drug Safety. <https://doi.org/10.1002/pds.1399>

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., & Moher, D. (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ, 337. <https://doi.org/10.1136/bmj.a2390>

Chapter 9 – Data protection and ethical aspects

9.1 – Patient and data protection

Commission Implementing Regulation (EU) No. 520/2012. (n.d.). Retrieved 29 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Data Privacy, Medical Record Confidentiality, and Research in the Interest of Public Health - International Society for Pharmacoepidemiology. (n.d.). International Society for Pharmacoepidemiology (ISPE). Retrieved 29 May 2020, from <https://www.pharmacoepi.org/resources/policies/privacy/>

Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data. (n.d.). Retrieved 29 May 2020, from <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:31995L0046&from=en>

Directive 2001/20/EC - Implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. (n.d.). Retrieved 29 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF>

Directive 2005/28/EC - Guidelines for good clinical practice. (n.d.). Retrieved 29 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:091:0013:0019:en:PDF>

EU Charter of Fundamental Rights. (n.d.). [Text]. European Commission - European Commission. Retrieved 29 May 2020, from https://ec.europa.eu/info/aid-development-cooperation-fundamental-rights/your-rights-eu/eu-charter-fundamental-rights_en

Guideline on good pharmacovigilance practices (GVP) Module VIII – Post-authorisation safety studies (Rev 3). (2018, September 17). European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP) - International Society for Pharmacoepidemiology. (2015). International Society for Pharmacoepidemiology. <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Proposal for a regulation on the protection of individuals with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and

repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC. (2017). EUR-Lex. <https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1511278760489&uri=CELEX:52017PC0008>

Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data. (n.d.). Retrieved 29 May 2020, from <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:008:0001:0022:EN:PDF>

Regulation (EU) 2016/679 - General Data Protection Regulation. (2016). EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?toc=OJ%3AL%3A2016%3A119%3ATOC&uri=uriserv%3AOJ.L_.2016.119.01.0001.01.ENG

Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. (n.d.). Retrieved 29 May 2020, from <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&rid=1>

9.2 – Scientific integrity and ethical conduct

Agency for Healthcare Research and Quality (AHRQ). (n.d.). Retrieved 4 June 2020, from <https://www.ahrq.gov/>

CIOMS International Ethical Guidelines for Health-related Research Involving Human. (n.d.). Retrieved 4 June 2020, from <https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf>

ENCePP Code of Conduct. (n.d.). ENCePP. Retrieved 4 June 2020, from http://www.encepp.eu/code_of_conduct/

Good Epidemiology Practices - IEA. (2007). International Epidemiological Association. http://ieaweb.org/IEAWeb/Content/IEA_Publications.aspx

Guidelines for Good Pharmacoepidemiology Practices (GPP) - International Society for Pharmacoepidemiology (ISPE). (n.d.). Retrieved 4 June 2020, from <https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

ICMJE - International Committee of Medical Journal Editors. (n.d.). Retrieved 4 June 2020, from <http://www.icmje.org/>

Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals (ICJME). (n.d.). Retrieved 4 June 2020, from <http://www.icmje.org/recommendations/>

Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition - Effective Health Care Program. (2014). <https://effectivehealthcare.ahrq.gov/products/registries-guide-3rd-edition/research/>

The European Union electronic Register of Post-Authorisation Studies (EU PAS Register). (n.d.). ENCePP. Retrieved 4 June 2020, from http://www.encepp.eu/encepp_studies/indexRegister.shtml

WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. (2013). <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

Kurz, X., Bauchau, V., Mahy, P., Glismann, S., Van der As, Lm., Simondon, F. (2017). The ADVANCE Code of Conduct for Collaborative Vaccine Studies. Vaccine. <https://doi.org/10.1016/j.vaccine.2017.02.039>

Chapter 10 – Specific topics

10.1 – Comparative effectiveness research – *This chapter has not been updated for Revision 8*

Agency for Healthcare Research and Quality (AHRQ). (n.d.). Retrieved April 5, 2018, from <https://www.ahrq.gov/>

AHRQ Comparative Effectiveness Reviews. (2005). Agency for Healthcare Research and Quality (US).

AHRQ. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. (n.d.). Retrieved from <https://www.effectivehealthcare.ahrq.gov/topics/observational-cer-protocol/research>

AHRQ. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. (n.d.). Retrieved from <https://effectivehealthcare.ahrq.gov/topics/cer-methods-guide/overview>

AHRQ. Summary Variables in Observational Research: Propensity Scores and Disease Risk Scores. Effective Health Care Program Research Report No. 33. May 2012. (n.d.). Retrieved from <https://effectivehealthcare.ahrq.gov/topics/observational-research-scores/research>

AHRQ. The Incident User Design in Comparative Effectiveness Research. Effective Health Care Program Research Report No. 33. May 2012. (n.d.). Retrieved from <https://effectivehealthcare.ahrq.gov/topics/incident-user-design/research>

Avorn J. (2007). In defense of Pharmacoepidemiology-Embracing the Yin and Yang of Drug Research. *N Engl J Med*, 357(22), 2219–2221. Retrieved from <http://www.nejm.org/doi/pdf/10.1056/NEJMp0706892>

Black, N. (1996). Why we need observational studies to evaluate the effectiveness of health care. *BMJ (Clinical Research Ed.)*, 312(7040), 1215–1218. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8634569>

Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User Survey. (n.d.). Retrieved April 9, 2018, from <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146444>

COMET - Core Outcome Measures in Effectiveness Trials Initiative. (n.d.). Retrieved April 9, 2018, from <http://www.comet-initiative.org/>

Crystal, S., Gaboda, D., Lucas, J., Gerhard, T., & Chakravarty, S. (2010). Assessing medication exposures and outcomes in the frail elderly: assessing research challenges in nursing home pharmacotherapy. *Medical Care*, 48(6 Suppl), S23-31. <https://doi.org/10.1097/MLR.0b013e3181de9d10>

DARTNet Institute. (n.d.). Retrieved April 9, 2018, from <http://www.dartnet.info/>

EUnetHTA. Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals. (n.d.). Retrieved April 9, 2018, from <https://www.eunetha.eu/the-final-version-of-hta-core-model-and-the-methodological-guidelines-for-rapid-rea-of-pharmaceuticals-is-now-available/>

European Network for Health Technology Assessment (EUnetHTA). (n.d.). Retrieved June 28, 2018, from <https://www.eunetha.eu/>

GRACE Principles - Good ReseArch for Comparative Effectiveness. (n.d.). Retrieved April 9, 2018, from <https://www.graceprinciples.org/>

GRADE Working Group. (n.d.). Retrieved June 28, 2018, from <http://www.gradeworkinggroup.org/>

GRADE working group. 6-part 2008 BMJ series. (n.d.). Retrieved from <http://www.cochrane.de/grade-publications#bmj>

GRADE working group. Journal of Clinical Epidemiology series of articles. (n.d.). Retrieved from <https://www.jclinepi.com/content/jce-GRADE-Series>

Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group. (n.d.). Retrieved April 9, 2018, from <http://www.gradeworkinggroup.org/>

Harker, J., & Kleijnen, J. (2012). What is a rapid review? A methodological exploration of rapid reviews in Health Technology Assessments. *International Journal of Evidence-Based Healthcare*, 10(4), 397–410. <https://doi.org/10.1111/j.1744-1609.2012.00290.x>

Hernán, M. A., & Robins, J. M. (2016). Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *American Journal of Epidemiology*, 183(8), 758–764. <https://doi.org/10.1093/aje/kwv254>

IMI GetReal. (n.d.). Retrieved June 28, 2018, from <http://www.imi-getreal.eu/>

International Society for Pharmacoeconomics and Outcome Research (ISPOR). (n.d.). Retrieved April 5, 2018, from <https://www.ispor.org/>

ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. (n.d.). Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartI.pdf>

ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. (n.d.). Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartII.pdf>

ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. (n.d.). Retrieved from <https://www.ispor.org/TaskForces/documents/RDPartIII.pdf>

Johnson, E. S., Bartman, B. A., Briesacher, B. A., Fleming, N. S., Gerhard, T., Kornegay, C. J., ... Schneeweiss, S. (2013). The incident user design in comparative effectiveness research. *Pharmacoepidemiology and Drug Safety*, 22(1), 1–6. <https://doi.org/10.1002/pds.3334>

Klungel, O. H., Martens, E. P., Psaty, B. M., Grobbee, D. E., Sullivan, S. D., Stricker, B. H. C., ... de Boer, A. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. *Journal of Clinical Epidemiology*, 57(12), 1223–1231. <https://doi.org/10.1016/j.jclinepi.2004.03.011>

Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015). The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ*, 350, h2147. <https://doi.org/10.1136/bmj.h2147>

Patient-Centered Outcome Research Institute (PCORI). (n.d.). Retrieved April 9, 2018, from <https://www.pcori.org/>

PCORI. Methodology Report. (2014, July 30). Retrieved April 9, 2018, from <https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-methodology-report>

Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs | NEJM. (n.d.). Retrieved April 9, 2018, from <http://www.nejm.org/doi/full/10.1056/NEJM200006223422507#t=article>

Ray, W. A. (2003). Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. *American Journal of Epidemiology*, 158(9), 915–920. <https://doi.org/10.1093/aje/kwq231>

- Real World Evidence Navigator. (n.d.). Retrieved April 9, 2018, from <https://rwe-navigator.eu/>
- S, S. (2007). Developments in Post-marketing Comparative Effectiveness Research. *Clinical Pharmacology and Therapeutics*, 82(2), 143–156. <https://doi.org/10.1038/sj.clpt.6100249>
- Sauer, B. C., Brookhart, A., Roy, J., & Vanderweele, T. (2013). A Review of Covariate Selection for Nonexperimental Comparative Effectiveness Research. *Pharmacoepidemiology and Drug Safety*, 22(11), 1139–1145. <https://doi.org/10.1002/pds.3506>
- Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of Clinical Epidemiology*, 58(4), 323–337. <https://doi.org/10.1016/j.jclinepi.2004.10.012>
- Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H and Brookhart MA. (2009). High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology*, 20(4), 512–522. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077219/pdf/nihms282669.pdf>
- Schwartz, D., & Lellouch, J. (2009). Explanatory and pragmatic attitudes in therapeutical trials. *Journal of Clinical Epidemiology*, 62(5), 499–505. <https://doi.org/10.1016/j.jclinepi.2009.01.012>
- Selby, J. V., Forsythe, L., & Sox, H. C. (2015). Stakeholder-Driven Comparative Effectiveness Research: An Update From PCORI. *JAMA*, 314(21), 2235–2236. <https://doi.org/10.1001/jama.2015.15139>
- Sox, H. C., & Goodman, S. N. (2012). The methods of comparative effectiveness research. *Annual Review of Public Health*, 33, 425–445. <https://doi.org/10.1146/annurev-publhealth-031811-124610>
- Staa, T.-P. van, Goldacre, B., Gulliford, M., Cassell, J., Pirmohamed, M., Taweel, A., ... Smeeth, L. (2012). Pragmatic randomised trials using routine electronic health records: putting them to the test. *BMJ*, 344, e55. <https://doi.org/10.1136/bmj.e55>
- Tadrous, M., Gagne, J. J., Stürmer, T., & Cadarette, S. M. (2013). Disease Risk Score (DRS) as a Confounder Summary Method: Systematic Review and Recommendations. *Pharmacoepidemiology and Drug Safety*, 22(2), 122–129. <https://doi.org/10.1002/pds.3377>
- Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... Chalkidou, K. (2009). A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *Canadian Medical Association Journal*, 180(10), E47–E57. <https://doi.org/10.1503/cmaj.090523>
- Toh, S., Gagne, J. J., Rassen, J. A., Fireman, B. H., Kulldorff, M., & Brown, J. S. (2013). Confounding adjustment in comparative effectiveness research conducted within distributed research networks. *Medical Care*, 51(8 Suppl 3), S4–10. <https://doi.org/10.1097/MLR.0b013e31829b1bb1>
- US National Library of Medicine: Queries on CER. (n.d.). [Other]. Retrieved April 9, 2018, from <https://www.nlm.nih.gov/hsrinfo/cer.html>
- Valuck, R. J., Anderson, H. O., Libby, A. M., Brandt, E., Bryan, C., Allen, R. R., ... Pace, W. D. (2012). Enhancing electronic health record measurement of depression severity and suicide ideation: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. *Journal of the American Board of Family Medicine: JABFM*, 25(5), 582–593. <https://doi.org/10.3122/jabfm.2012.05.110053>
- When are observational studies as credible as randomised trials? - *The Lancet*. (n.d.). Retrieved April 9, 2018, from [http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(04\)16261-2.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(04)16261-2.pdf)

Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., ... Moher, D. (2008). Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*, 337, a2390. <https://doi.org/10.1136/bmj.a2390>

10.2 – Vaccine effectiveness

A framework for research on vaccine effectiveness. (2018). *Vaccine*, 36(48), 7286–7293.

<https://doi.org/10.1016/j.vaccine.2018.04.016>

ADVANCE - Report on appraisal of vaccine safety methods. (n.d.). Retrieved 8 June 2020, from

https://vac4eu.org/wp-content/uploads/2019/03/ADVANCE_D4-2_appraisal-safety-methods_final_PU.pdf

Andrews, N., Waight, P. A., Borrow, R., Ladhani, S., George, R. C., Slack, M. P. E., & Miller, E. (2011).

Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales. *PLOS ONE*, 6(12), e28435.

<https://doi.org/10.1371/journal.pone.0028435>

Baker, M. A., Baer, B., Kulldorff, M., Zichittella, L., Reindel, R., DeLuccia, S., Lipowicz, H., Freitas, K., Jin, R., & Yih, W. K. (2019). Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. *PLoS Medicine*, 16(7).

<https://doi.org/10.1371/journal.pmed.1002844>

Beck, Cr. et al. (2012). Influenza Vaccination for Immunocompromised Patients: Systematic Review and Meta-Analysis by Etiology. *The Journal of Infectious Diseases*.

<https://doi.org/10.1093/infdis/jis487>

Biggart, R. et al. Lack of impact of rotavirus vaccination on childhood seizure hospitalizations in England – An interrupted time series analysis. (2018). *Vaccine*, 36(31), 4589–4592.

<https://doi.org/10.1016/j.vaccine.2018.06.029>

Black, S. et al. (2009). Importance of Background Rates of Disease in Assessment of Vaccine Safety During Mass Immunisation With Pandemic H1N1 Influenza Vaccines. *Lancet* (London, England).

[https://doi.org/10.1016/S0140-6736\(09\)61877-8](https://doi.org/10.1016/S0140-6736(09)61877-8)

Bollaerts, K. et al. (2019). Observational Studies of Non-Specific Effects of Diphtheria-Tetanus-Pertussis Vaccines in Low-Income Countries: Assessing the Potential Impact of Study Characteristics, Bias and Confounding Through Meta-Regression. *Vaccine*.

<https://doi.org/10.1016/j.vaccine.2018.11.049>

Brighton Collaboration - Home Page. (n.d.). Brighton Collaboration. Retrieved 8 June 2020, from

<https://brightoncollaboration.us/>

Brown, Js. et al. (2007). Early Detection of Adverse Drug Events Within Population-Based Health Networks: Application of Sequential Testing Methods. *Pharmacoepidemiology and Drug Safety*.

<https://doi.org/10.1002/pds.1509>

Carvajal, A. et al. (2011). Adverse Events Associated With Pandemic Influenza Vaccines: Comparison of the Results of a Follow-Up Study With Those Coming From Spontaneous Reporting. *Vaccine*.

<https://doi.org/10.1016/j.vaccine.2010.10.067>

Castilla, J. et al. (2012). Effectiveness of Rotavirus Vaccines in Preventing Cases and Hospitalizations Due to Rotavirus Gastroenteritis in Navarre, Spain. *Vaccine*.

<https://doi.org/10.1016/j.vaccine.2011.11.071>

CIOMS Guide to Vaccine Safety Communication. (2018). Council for International Organizations of Medical Sciences. <https://cioms.ch/publications/product/cioms-guide-vaccine-safety-communication/>

de Bie, S. et al. (2012). Vaccine-based Subgroup Analysis in VigiBase: Effect on Sensitivity in Paediatric Signal Detection. *Drug Safety*. <https://doi.org/10.2165/11598120-000000000-00000>

De Serres, G. et al. (2012). Use of Surveillance Data to Estimate the Effectiveness of the 7-valent Conjugate Pneumococcal Vaccine in Children Less Than 5 Years of Age Over a 9 Year Period. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2012.04.017>

De Smedt, T. et al. (2018). Bias Due to Differential and Non-Differential Disease- And Exposure Misclassification in Studies of Vaccine Effectiveness. *PloS One*. <https://doi.org/10.1371/journal.pone.0199180>

De Vito, C. et al. (2007). A Systematic Review Evaluating the Potential for Bias and the Methodological Quality of Meta-Analyses in Vaccinology. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2007.10.034>

Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., & Sturkenboom, M. (2011). Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. *BMJ*, 343. <https://doi.org/10.1136/bmj.d3908>

Drolet, M. et al. (2019). Population-level Impact and Herd Effects Following the Introduction of Human Papillomavirus Vaccination Programmes: Updated Systematic Review and Meta-Analysis. *Lancet* (London, England). [https://doi.org/10.1016/S0140-6736\(19\)30298-3](https://doi.org/10.1016/S0140-6736(19)30298-3)

Dudareva-Vizule, S. et al. (2012). Impact of Rotavirus Vaccination in Regions With Low and Moderate Vaccine Uptake in Germany. *Human Vaccines & Immunotherapeutics*. <https://doi.org/10.4161/hv.21593>

Effectiveness of rotavirus vaccination – Generic study protocol for retrospective case control studies based on computerised databases - ECDC. (n.d.). Retrieved 8 June 2020, from <https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/rotavirus-vaccination-case-control-april2013.pdf>

Effectiveness of rotavirus vaccination – Generic study protocol for retrospective cohort studies based on computerised databases - ECDC. (n.d.). Retrieved 8 June 2020, from <https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/rotavirus-vaccination-cohort-study-april2013.pdf>

Epidemiological Designs for Vaccine Safety Assessment: Methods and Pitfalls. *Biologicals : Journal of the International Association of Biological Standardization*. <https://doi.org/10.1016/j.biologicals.2011.08.010>

Escolano, S. (2013). A New Self-Controlled Case Series Method for Analyzing Spontaneous Reports of Adverse Events After Vaccination. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwt128>

Escolano, S., Farrington, C. P., Hill, C., & Tubert-Bitter, P. (2011). Intussusception after Rotavirus Vaccination — Spontaneous Reports. *New England Journal of Medicine*, 365(22), 2139–2139. <https://doi.org/10.1056/NEJMc1107771>

European Centre for Disease Prevention and Control. (n.d.). Retrieved 8 June 2020, from <https://www.ecdc.europa.eu/en>

Evans, S. J. W. (2008). Stratification for Spontaneous Report Databases. *Drug Safety*, 31(11), 1049–1052. <https://doi.org/10.2165/00002018-200831110-00009>

Exploring the Feasibility of Conducting Vaccine Effectiveness Studies - Sentinel (2018). (n.d.). Retrieved 8 June 2020, from

https://www.sentinelinitiative.org/sites/default/files/Methods/Sentinel_PRISM_Vaccine_Effectiveness_White_Paper.pdf

Farrington, Cp. (2004). Control Without Separate Controls: Evaluation of Vaccine Safety Using Case-Only Methods. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2004.01.017>

Farrington, Cp. et al. (2009). Epidemiological Studies of the Non-Specific Effects of Vaccines: II--methodological Issues in the Design and Analysis of Cohort Studies. *Tropical Medicine & International Health : TM & IH*. <https://doi.org/10.1111/j.1365-3156.2009.02302.x>

Fine, Pe. et al. (2009). Epidemiological Studies of the 'Non-Specific Effects' of Vaccines: I--data Collection in Observational Studies. *Tropical Medicine & International Health : TM & IH*. <https://doi.org/10.1111/j.1365-3156.2009.02301.x>

GAIA project. (2016). Harmonising Immunisation Safety Assessment in Pregnancy. *Vaccine*, 34(49). <https://www.sciencedirect.com/journal/vaccine/vol/34/issue/49>

GAIA project. (2017). Harmonising Immunisation Safety Assessment in Pregnancy - Part II. *Vaccine*, 35(48). <https://www.sciencedirect.com/journal/vaccine/vol/35/issue/48/part/PA>

Glanz, Jm. et al. (2006). Four Different Study Designs to Evaluate Vaccine Safety Were Equally Validated With Contrasting Limitations. *Journal of Clinical Epidemiology*. <https://doi.org/10.1016/j.jclinepi.2005.11.012>

Greene, Sk. et al. (2010). Near Real-Time Surveillance for Influenza Vaccine Safety: Proof-Of-Concept in the Vaccine Safety Datalink Project. *American Journal of Epidemiology*. <https://doi.org/10.1093/aje/kwp345>

Guideline on good pharmacovigilance practices (GVP) - Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases [Text]. European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices>

Halloran, M. E., Haber, M., Longini, I. M., & Struchiner, C. J. (1991). Direct and Indirect Effects in Vaccine Efficacy and Effectiveness. *American Journal of Epidemiology*, 133(4), 323–331. <https://doi.org/10.1093/oxfordjournals.aje.a115884>

Hanquet, G. et al. (2013). Vaccine Effects and Impact of Vaccination Programmes in Post-Licensure Studies. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2013.07.006>

Heffernan, J. M., & Keeling, M. J. (2009). Implications of vaccination and waning immunity. *Proceedings of the Royal Society B: Biological Sciences*, 276(1664), 2071–2080. <https://doi.org/10.1098/rspb.2009.0057>

Heininger, U. et al. (2017). Guide to Active Vaccine Safety Surveillance: Report of CIOMS Working Group on Vaccine Safety - Executive Summary. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2017.06.033>

Hennessy, S. et al. (1996). Effectiveness of Live-Attenuated Japanese Encephalitis Vaccine (SA14-14-2): A Case-Control Study. *Lancet (London, England)*. [https://doi.org/10.1016/s0140-6736\(96\)91075-2](https://doi.org/10.1016/s0140-6736(96)91075-2)

Hocine, Mn. et al. (2007). Hepatitis B Vaccination and First Central Nervous System Demyelinating Events: Reanalysis of a Case-Control Study Using the Self-Controlled Case Series Method. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2007.05.032>

- Hviid, A. et al. (2018). Human Papillomavirus Vaccination of Adult Women and Risk of Autoimmune and Neurological Diseases. *Journal of Internal Medicine*. <https://doi.org/10.1111/joim.12694>
- Impact of rotavirus vaccination – Generic study protocol - ECDC. (n.d.). Retrieved 8 June 2020, from <https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Rotavirus-impact-vaccination-April-2013.pdf>
- Jackson, MI et al. (2013). The Test-Negative Design for Estimating Influenza Vaccine Effectiveness. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2013.02.053>
- Jefferson, T. et al. (2005). Efficacy and Effectiveness of Influenza Vaccines in Elderly People: A Systematic Review. *Lancet* (London, England). [https://doi.org/10.1016/S0140-6736\(05\)67339-4](https://doi.org/10.1016/S0140-6736(05)67339-4)
- Klein, N. P. (2011). Vaccine safety in special populations. *Human Vaccines*, 7(2), 269–271. <https://doi.org/10.4161/hv.7.2.13860>
- Kurz, X. et al. (2011). Safety Monitoring of Influenza A/H1N1 Pandemic Vaccines in EudraVigilance. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2011.04.005>
- Leino, T. et al. (2012). First Year Experience of Rotavirus Immunisation Programme in Finland. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2012.10.068>
- Leite, A., Andrews, N. J., & Thomas, S. L. (2016). Near real-time vaccine safety surveillance using electronic health records—a systematic review of the application of statistical methods. *Pharmacoepidemiology and Drug Safety*, 25(3), 225–237. <https://doi.org/10.1002/pds.3966>
- Mahaux, O., Bauchau, V., & Van Holle, L. (2016a). Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. *Pharmacoepidemiology and Drug Safety*, 25(2), 215–222. <https://doi.org/10.1002/pds.3918>
- Mahaux, O., Bauchau, V., & Van Holle, L. (2016b). Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. *Pharmacoepidemiology and Drug Safety*, 25(2), 215–222. <https://doi.org/10.1002/pds.3918>
- Marin, M., Marti, M., Kambhampati, A., Jeram, S. M., & Seward, J. F. (2016). Global Varicella Vaccine Effectiveness: A Meta-analysis. *Pediatrics*, 137(3). <https://doi.org/10.1542/peds.2015-3741>
- Martín Arias, Lh. et al. (2015). Guillain-Barré Syndrome and Influenza Vaccines: A Meta-Analysis. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2015.05.013>
- McClure, DI. et al. (2008). Comparison of Epidemiologic Methods for Active Surveillance of Vaccine Safety. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2008.03.074>
- Miller, E. et al. Risk of Narcolepsy in Children and Young People Receiving AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine: Retrospective Analysis - PubMed. (n.d.). <https://doi.org/10.1136/bmj.f794>
- MODULE 4 – Surveillance - WHO Vaccine Safety Basics. (n.d.). WHO Vaccine Safety Basics. Retrieved 8 June 2020, from <https://vaccine-safety-training.org/overview-and-outcomes-4.html>
- Nelson, Jc. et al. (2012). Challenges in the Design and Analysis of Sequentially Monitored Postmarket Safety Surveillance Evaluations Using Electronic Observational Health Care Data. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.2324>
- Organization, W. H. (2017). Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies. World Health Organization. <https://apps.who.int/iris/handle/10665/255203>

Polyzos, Ka. et al. (2015). Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. *Obstetrics and Gynecology*.
<https://doi.org/10.1097/AOG.0000000000001068>

Rasmussen, T. A., Jørgensen, M. R. S., Bjerrum, S., Jensen-Fangel, S., Støvring, H., Østergaard, L., & Søgaard, O. S. (2012). Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. *The BMJ*, 345. <https://doi.org/10.1136/bmj.e5823>

Remschmidt, C., Rieck, T., Bödeker, B., & Wichmann, O. (2015). Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany. *BMC Infectious Diseases*, 15. <https://doi.org/10.1186/s12879-015-0882-3>

Report of the CIOMS/WHO Working Group on Definition and Application of Terms for Vaccine Pharmacovigilance (2012). (n.d.). Retrieved 8 June 2020, from
https://www.who.int/vaccine_safety/initiative/tools/CIOMS_report_WG_vaccine.pdf

Rondy, M. et al. (2015). 2012/13 Influenza Vaccine Effectiveness Against Hospitalised Influenza A(H1N1)pdm09, A(H3N2) and B: Estimates From a European Network of Hospitals. *Euro Surveillance : Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*. <https://doi.org/10.2807/1560-7917.es2015.20.2.21011>

Salmon, Da. et al. (2013). Association Between Guillain-Barré Syndrome and Influenza A (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis. *Lancet (London, England)*.
[https://doi.org/10.1016/S0140-6736\(12\)62189-8](https://doi.org/10.1016/S0140-6736(12)62189-8)

Siegrist, Ca. et al. (2007). Human Papilloma Virus Immunization in Adolescent and Young Adults: A Cohort Study to Illustrate What Events Might Be Mistaken for Adverse Reactions. *The Pediatric Infectious Disease Journal*. <https://doi.org/10.1097/INF.0b013e318149dfea>

Simpson, Cr. et al. (2015). Trivalent Inactivated Seasonal Influenza Vaccine Effectiveness for the Prevention of Laboratory-Confirmed Influenza in a Scottish Population 2000 to 2009. *Euro Surveillance : Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*. <https://doi.org/10.2807/1560-7917.es2015.20.8.21043>

Sullivan, Sg. et al. (2016). Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. *American Journal of Epidemiology*.
<https://doi.org/10.1093/aje/kww064>

Systematic overview of data sources for drug safety in pregnancy research Consultancy. (n.d.). Retrieved 8 June 2020, from
http://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf

Tavares-Da-Silva, F. et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. (2020). *Vaccine*, 38(18), 3489–3500. <https://doi.org/10.1016/j.vaccine.2019.11.058>

Tokars, Ji. et al. (2012). The Risk of Guillain-Barré Syndrome Associated With Influenza A (H1N1) 2009 Monovalent Vaccine and 2009-2010 Seasonal Influenza Vaccines: Results From Self-Controlled Analyses. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3220>

Vaccine Effectiveness Simulation. (n.d.). Retrieved 8 June 2020, from <https://apps-p-95.com/VEMisclassification/>

Vaccine Safety Datalink (VSD). (2019, June 17).
<https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html>

Van Ganse, E. et al. (2012). Health Problems Most Commonly Diagnosed Among Young Female Patients During Visits to General Practitioners and Gynecologists in France Before the Initiation of the Human Papillomavirus Vaccination Program. *Pharmacoepidemiology and Drug Safety*.

<https://doi.org/10.1002/pds.2243>

Van Holle, L. et al. (2013). Optimization of a Quantitative Signal Detection Algorithm for Spontaneous Reports of Adverse Events Post Immunization. *Pharmacoepidemiology and Drug Safety*.

<https://doi.org/10.1002/pds.3392>

Verani, Jr. et al. (2017). Case-control Vaccine Effectiveness Studies: Data Collection, Analysis and Reporting Results. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2017.04.035>

Verani, Jr. et al. (2017). Case-control Vaccine Effectiveness Studies: Preparation, Design, and Enrollment of Cases and Controls. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2017.04.037>

Wacholder, S. et al. (2010). Risk of Miscarriage With Bivalent Vaccine Against Human Papillomavirus (HPV) Types 16 and 18: Pooled Analysis of Two Randomised Controlled Trials. *BMJ (Clinical Research Ed.)*. <https://doi.org/10.1136/bmj.c712>

Whitaker, J. A., Ovsyannikova, I. G., & Poland, G. A. (2015). Adversomics: a new paradigm for vaccine safety and design. *Expert Review of Vaccines*, 14(7), 935–947.

<https://doi.org/10.1586/14760584.2015.1038249>

WHO Vaccine Safety Basics. (n.d.). Retrieved 8 June 2020, from <https://vaccine-safety-training.org/home.html>

Wiyeh, A. B., Abdullahi, L. H., Wonkam, A., Wiysonge, C. S., & Kaba, M. (2018). Effects of vaccines in patients with sickle cell disease: a systematic review protocol. *BMJ Open*, 8(3), e021140.

<https://doi.org/10.1136/bmjopen-2017-021140>

Woo, Ej. et al. (2008). Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS). *Drug Safety*. <https://doi.org/10.2165/00002018-200831080-00003>

Xu, R. et al. (2012). Assessing the Effect of Vaccine on Spontaneous Abortion Using Time-Dependent Covariates Cox Models. *Pharmacoepidemiology and Drug Safety*. <https://doi.org/10.1002/pds.3301>

Yanni, E. A., Ferreira, G., Guennec, M., El Hahi, Y., El Ghachi, A., Haguinet, F., Espie, E., & Bianco, V. (2018). Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. *BMJ Open*, 8(6).

<https://doi.org/10.1136/bmjopen-2017-020528>

Yih, Wk. et al. (2011). Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project. *Pediatrics*. <https://doi.org/10.1542/peds.2010-1722I>

10.3 – Design and analysis of pharmacogenetic studies – *This chapter has not been updated for Revision 8*

Amstutz, U., Shear, N. H., Rieder, M. J., Hwang, S., Fung, V., Nakamura, H., CPNDS clinical recommendation group. (2014). Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. *Epilepsia*, 55(4), 496–506.

<https://doi.org/10.1111/epi.12564>

Balding, D. J. (2006). A tutorial on statistical methods for population association studies. *Nature Reviews. Genetics*, 7(10), 781–791. <https://doi.org/10.1038/nrg1916>

Bozkurt, O., Verschuren, W. M. M., van Wieren-de Wijer, B. M. A., Knol, M. J., de Boer, A., Grobbee, D. E., Klungel, O. H. (2008). Genetic variation in the renin-angiotensin system modifies the beneficial

effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. *Journal of Human Hypertension*, 22(11), 774–780. <https://doi.org/10.1038/jhh.2008.62>

Carleton, B., Poole, R., Smith, M., Leeder, J., Ghannadan, R., Ross, C., Hayden, M. (2009). Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. *Pharmacoepidemiology and Drug Safety*, 18(8), 713–721. <https://doi.org/10.1002/pds.1772>

Carr, D. F., O'Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., Pirmohamed, M. (2013). SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. *Clinical Pharmacology and Therapeutics*, 94(6), 695–701. <https://doi.org/10.1038/clpt.2013.161>

CPIC: Clinical Pharmacogenetics Implementation Consortium. (n.d.). Retrieved April 9, 2018, from <https://cpicpgx.org/>

Dennis, J., Hawken, S., Krewski, D., Birkett, N., Gheorghe, M., Frei, J., Little, J. (2011). Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. *International Journal of Epidemiology*, 40(5), 1329–1341. <https://doi.org/10.1093/ije/dyr088>

Drews, J. (2000). Drug discovery: a historical perspective. *Science (New York, N.Y.)*, 287(5460), 1960–1964.

Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. *Science (New York, N.Y.)*, 286(5439), 487–491.

Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. *Nature*, 429(6990), 464–468. <https://doi.org/10.1038/nature02626>

Gatto, N. M., Campbell, U. B., Rundle, A. G., & Ahsan, H. (2004). Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias. *International Journal of Epidemiology*, 33(5), 1014–1024. <https://doi.org/10.1093/ije/dyh306>

Grady, B. J., & Ritchie, M. D. (2011). Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis. *Current Pharmacogenomics and Personalized Medicine*, 9(1), 41–66. <https://doi.org/10.2174/187569211794728805>

Guideline for data analysis of genomewide association studies. (n.d.). Retrieved April 9, 2018, from <https://www.ncbi.nlm.nih.gov/pubmed/17726238>

Jorgensen, A. L., & Williamson, P. R. (2008). Methodological quality of pharmacogenetic studies: issues of concern. *Statistics in Medicine*, 27(30), 6547–6569. <https://doi.org/10.1002/sim.3420>

Khoury, M. J., & Flanders, W. D. (1996). Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! *American Journal of Epidemiology*, 144(3), 207–213. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8686689>

Little, J., Higgins, J. P. T., Ioannidis, J. P. A., Moher, D., Gagnon, F., von Elm, E., Birkett, N. (2009). STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. *European Journal of Clinical Investigation*, 39(4), 247–266. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19297801>

Liu, Y., Nyunoya, T., Leng, S., Belinsky, S. A., Tesfaigzi, Y., & Bruse, S. (2013). Softwares and methods for estimating genetic ancestry in human populations. *Human Genomics*, 7, 1. <https://doi.org/10.1186/1479-7364-7-1>

- Madadi, P., Amstutz, U., Rieder, M., Ito, S., Fung, V., Hwang, S., CPNDS Clinical Recommendations Group. (2013). Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. *Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharamcologie Clinique*, 20(3), e369-396. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/24214521>
- Molokhia, M., & McKeigue, P. (2006). EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics*, 7(4), 633-638. <https://doi.org/10.2217/14622416.7.4.633>
- Peters, B. J. M., Rodin, A. S., de Boer, A., & Maitland-van der Zee, A.-H. (2010). Methodological and statistical issues in pharmacogenomics. *The Journal of Pharmacy and Pharmacology*, 62(2), 161-166. <https://doi.org/10.1211/jpp.62.02.0002>
- PharmGKB (The Pharmacogenomics Knowledgebase). (n.d.). Retrieved April 9, 2018, from <https://www.pharmgkb.org/>
- Pritchard, J. K., Stephens, M., Rosenberg, N. A., & Donnelly, P. (2000). Association Mapping in Structured Populations. *American Journal of Human Genetics*, 67(1), 170-181. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287075/>
- Psaty, B. M., Smith, N. L., Heckbert, S. R., Vos, H. L., Lemaitre, R. N., Reiner, A. P., Rosendaal, F. R. (2002). Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. *JAMA*, 287(13), 1680-1689. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11926892>
- Ross, S., Anand, S. S., Joseph, P., & Paré, G. (2012). Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. *JRSM Cardiovascular Disease*, 1(1). <https://doi.org/10.1258/cvd.2012.012001>
- Storey, J. D., & Tibshirani, R. (2003). Statistical significance for genomewide studies. *Proceedings of the National Academy of Sciences of the United States of America*, 100(16), 9440-9445. <https://doi.org/10.1073/pnas.1530509100>
- van der Baan, F. H., Klungel, O. H., Egberts, A. C. G., Leufkens, H. G., Grobbee, D. E., Roes, K. C. B., & Knol, M. J. (2011). Pharmacogenetics in randomized controlled trials: considerations for trial design. *Pharmacogenomics*, 12(10), 1485-1492. <https://doi.org/10.2217/pgs.11.95>
- van der Baan, F. H., Knol, M. J., Klungel, O. H., Egberts, A. C., Grobbee, D. E., & Roes, K. C. B. (2012). Potential of adaptive clinical trial designs in pharmacogenetic research. *Pharmacogenomics*, 13(5), 571-578. <https://doi.org/10.2217/pgs.12.10>
- van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A.-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Klungel, O. H. (2009). Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. *Journal of Hypertension*, 27(1), 61-68. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/19145769>